DOMÍNIOS DE LIGAÇÃO AO ANTÍGENO CD3 OTIMIZADOS
CD3 antigen-binding domains with optimized CDR sequences and lambda charge pairs address the need for safe T cell activation, enhancing cancer treatment efficacy through reduced cytokine release.
Patent Information
- Application Number
- BR112025021622
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-10
- Filing Date
- 2024-04-09
- Publication Date
- 2026-11-10
AI Technical Summary
There is a need for antibodies that can bind to CD3 with optimized affinity to induce T cell activation without excessive cytokine release and safety concerns.
Development of CD3 antigen-binding domains with specific CDR sequences in VH and VL regions, and introduction of lambda charge pairs at defined positions to enhance light chain pairing, enabling the creation of multispecific antibodies that effectively engage T cells for cancer treatment.
The antibodies achieve effective T cell activation with reduced cytokine release, making them suitable for cancer immunotherapy by ensuring safe and efficient engagement.
Abstract
Description
1 / 92 OPTIMIZED CD3 ANTIGEN BINDING DOMAINS CROSS-REFERENCE TO RELATED DEPOSIT REQUESTS
[0001] This application claims the benefit of US provisional patent application no. 63 / 495.127, filed on April 10, 2023, which is incorporated herein by reference in its entirety. REFERENCE TO THE ELECTRONICALLY SUBMITTED SEQUENCE LISTING
[0002] The content of the electronically submitted sequence listing (Name: The IOTS-102-WO Sequence Listing.xml file (Size: 109086 bytes; and Creation Date: March 29, 2024), filed with the application, is incorporated herein by reference in its entirety. FIELD OF REVELATION
[0003] The present disclosure relates to antibodies or fragments thereof comprising an antigen-binding domain capable of binding to a CD3 protein or a fragment thereof. The disclosure also relates to methods of producing these antibodies and their therapeutic uses. BACKGROUND
[0004] T cells recognize antigenic peptides through a complex of heterodimeric T cell receptor (TCR) α and β chains, in combination with four CD3 subunits, denoted ε, γ, δ, ζ (Kindt et al., 2007). After TCR-mediated antigen recognition, CD3 is essential for the transmission of TCR-activated signaling through immunoreceptor tyrosine activating motifs (ITAMs) (Letourneur et al., 1992). There remains a need for more antibodies, particularly multispecific antibodies, that are able to bind to CD3 and transmit TCR-activated signaling safely and effectively. SUMMARY OF REVELATION
[0005] Consequently, there is a need in the technique for antibodies that bind to CD3 with optimized affinity to induce T cell activation, but without being associated with excessive cytokine release and tolerability. Petition 870260111560, dated 10 / 29 / 2026, page 6 / 219 2 / 92 reduced. The present disclosure involved an extensive affinity selection and maturation program to isolate a panel of CD3 antibodies that are capable of binding to CD3 and inducing T cell activation. These molecules are expected to achieve therapeutic benefit by ensuring effective T cell engagement, but without the safety concerns attributed to antibodies that bind to CD3 with a high affinity or cytokine release profile, making them suitable for cancer treatment as immunotherapeutic agents.
[0006] Consequently, in one aspect, an antibody is provided here comprising an antigen-binding domain capable of binding to a CD3 protein or a fragment thereof, wherein the CD3 antigen-binding domain comprises a variable heavy chain (VH) region according to any of the following: a VH region comprising the following CDRs: HCDR1 with the amino acid sequence SEQ ID NO: 90; HCDR2 with the amino acid sequence of SEQ ID NO: 91; and HCDR3 with the amino acid sequence of SEQ ID NO: 92, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:82; HCDR2 with the amino acid sequence SEQ ID NO: 83;e HCDR3 with the amino acid sequence SEQ ID NO:84, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:78; HCDR2 with the amino acid sequence SEQ ID NO: 79;e HCDR3 with the amino acid sequence SEQ ID NO:80, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:66; HCDR2 with the amino acid sequence SEQ ID NO: 67;e HCDR3 with the amino acid sequence SEQ ID NO:68, Petition 870260111560, dated 10 / 29 / 2026, p. 7 / 219 3 / 92 a VH region comprising the following CDRs: HCDR1 with the amino acid sequence SEQ ID NO: 70; HCDR2 with the amino acid sequence of SEQ ID NO: 71; and HCDR3 with the amino acid sequence SEQ ID NO: 72, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence SEQ ID NO:74; HCDR2 with the amino acid sequence SEQ ID NO: 75;e HCDR3 with the amino acid sequence SEQ ID NO:76, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:86; HCDR2 with the amino acid sequence SEQ ID NO: 87;e HCDR3 with the amino acid sequence SEQ ID NO:88, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence SEQ ID NO:94; HCDR2 with the amino acid sequence SEQ ID NO: 95;e HCDR3 with the amino acid sequence SEQ ID NO: 96, and a VH region comprising the following CDRs: HCDR1 with the amino acid sequence SEQ ID NO:98; HCDR2 with the amino acid sequence SEQ ID NO: 99;e HCDR3 with the amino acid sequence SEQ ID NO:100, and the antigen-binding domain CD3 comprising a variable heavy chain (VH) region according to any of the following: a VL region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:46; HCDR2 with the amino acid sequence SEQ ID NO: 47;e HCDR3 with the amino acid sequence SEQ ID NO:48, a VL region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:58; HCDR2 with the amino acid sequence SEQ ID NO: 59;e Petition 870260111560, dated 10 / 29 / 2026, p. 8 / 219 4 / 92 HCDR3 with the amino acid sequence SEQ ID NO: 60, and a VL region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:62; HCDR2 with the amino acid sequence SEQ ID NO: 63;e HCDR3 with the amino acid sequence SEQ ID NO:64.
[0007] In some cases, the CD3 antigen-binding domain comprises a VH region and a VL region comprising one of the following sets of CDRs: I.HCDR1 with the amino acid sequence SEQ ID NO: 90. ii. HCDR2 with amino acid sequence SEQ ID NO: 91, iii. HCDR3 with amino acid sequence SEQ ID NO: 92, iv. LCDR1 with amino acid sequence SEQ ID NO: 46, v. LCDR2 with amino acid sequence SEQ ID NO: 47, vi. LCDR3 with amino acid sequence SEQ ID NO: 48; or i. HCDR1 with amino acid sequence SEQ ID NO: 82, ii. HCDR2 with amino acid sequence SEQ ID NO: 83, iii. HCDR3 with amino acid sequence SEQ ID NO: 84, iv. LCDR1 with amino acid sequence SEQ ID NO: 46, v. LCDR2 with amino acid sequence SEQ ID NO: 47, vi. LCDR3 with amino acid sequence SEQ ID NO: 48; or i. HCDR1 with amino acid sequence SEQ ID NO: 78 ii. HCDR2 with amino acid sequence SEQ ID NO: 79 iii. HCDR3 with amino acid sequence SEQ ID NO: 80, iv. LCDR1 with amino acid sequence SEQ ID NO: 62, v. LCDR2 with amino acid sequence SEQ ID NO: 63, vi.LCDR3 with the amino acid sequence SEQ ID NO: 64.
[0008] In some cases, the VH domain of the CD3 antigen-binding domain comprises an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. Petition 870260111560, dated 10 / 29 / 2026, page 9 / 219 5 / 92 with SEQ ID NO: 77, SEQ ID NO: 89, or SEQ ID NO: 81. In some cases, the VL domain of the CD3 antigen-binding domain comprises an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 45 or SEQ ID NO: 61.
[0009] In some cases, the CD3 antigen-binding domain comprises: i. a VH region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 77, and a VL region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 61; ii. a VH region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 89, and a VL region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 45 or iii. a VH region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 81, and a VL region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 45.
[0010] As described above, CD3 antigen-binding domains find specific utility when used in the context of a multispecific antibody containing an antigen-binding domain that is capable of binding to another target.For example, the CD3 antigen-binding domains described here could be part of a multispecific antibody that is capable of binding to CD3 and another target, for example, a tumor-associated antigen (TAA). Examples of suitable TAAs are described here.
[0011] Consequently, in some cases, the antibody additionally comprises a target antigen-binding domain. In some cases, the target antigen-binding domain is capable of binding to a tumor-associated antigen (TAA). In some cases, the antibody is in a '2+1' format, where the antibody Petition 870260111560, dated 10 / 29 / 2026, p. 10 / 219 6 / 92 contains a single CD3 antigen-binding domain that binds monovalently to CD3 and two target antigen-binding domains that bind bivalently to the target (e.g., TAA). In some cases, the antibody is in a trispecific, trivalent format containing three antigen-binding domains.
[0012] When it comes to generating multispecific antibodies containing multiple antigen-binding arms formed from different light and heavy chains, promiscuous pairing of heavy and light chains can present challenges. As described here, amino acid residues at the interface between a light chain and a lambda heavy chain were identified where charge pairs could be introduced, demonstrating that the introduction of these lambda charge pairs could advantageously improve chain pairing beyond what was achieved in a previous antibody format.As further described herein, these charge variants can be used to efficiently produce multispecific antibodies in different formats, including a bispecific '2+1' format and a trivalent and trispecific format.
[0013] Consequently, an antigen-binding domain in the antibody (e.g., the CD3 antigen-binding arm) contains a pair of lambda charges between the lambda region of the constant light chain (CLA) and the constant heavy chain 1 (CH1) region of that antigen-binding arm, wherein the antigen-binding domain comprises a pair of lambda charges situated in one or more of the following pairs of positions: (i) position 117 in CLA and position 141 in CH1; (ii) position 117 in CLA and position 185 in CH1; (iii) position 119 in CLA and position 128 in CH1; (iv) position 134 in CLA and position 128 in CH1; (v) position 134 in CLA and position 145 in CH1; (vi) position 134 in CLA and position 183 in CH1; (vii) position 136 in CLA and position 185 in CH1; (viii) position 178 in CLA and position 173 in CH1; and Petition 870260111560, dated 10 / 29 / 2026, page 11 / 219 7 / 92 (ix) position 117 in CLÃ and position 187 in CH1, wherein the lambda charge pair comprises a positively charged amino acid residue optionally selected from arginine, lysine or histidine situated in one of the positions in the lambda charge pair and a negatively charged amino acid residue optionally selected from aspartic acid, glutamic acid, serine or threonine situated in the other position in the lambda charge pair, and wherein the numbering is in accordance with the EU index.
[0014] In some cases, an antigen-binding arm in the antibody (e.g., the CD3 antigen-binding arm) contains a lambda charge pair located at position 117 on CLÃ and at position 141 on CH1, wherein the lambda charge pair comprises a positively charged amino acid residue selected from arginine, lysine, or histidine located at one position on the lambda charge pair and a negatively charged amino acid residue selected from aspartic acid, glutamic acid, serine, or threonine located at the other position on the lambda charge pair.
[0015] As further described herein, lambda charge pairs can be combined with other approaches to encourage light chain pairing, for example, in order to further enhance the correct assembly of the desired multispecific antibody.
[0016] In some cases, the antibody comprises a CD3 antigen-binding domain and a CD8 antigen-binding domain. For example, the antibody may comprise a CD3 antigen-binding domain, a TAA antigen-binding domain, and a CD8 antigen-binding domain. The CD8 antigen-binding domain may be a VHH molecule (e.g., fused to the bispecific 2+1 format described herein). The CD8 antigen-binding domain may be an antigen-binding arm ('Fab') (e.g., one of the antigen-binding arms in the trispecific antibody format described herein). Petition 870260111560, dated 10 / 29 / 2026, page 12 / 219 8 / 92
[0017] Pharmaceutical compositions comprising the antibody described herein, as further defined herein, are also provided. Antibody molecules and pharmaceutical compositions, all as defined herein, are also provided for use in a method of treating the human or animal body, such as a method of treating cancer. Methods of treating cancer comprising the administration of an antibody or a pharmaceutical composition as defined herein are also provided.
[0018] Nucleic acids, vectors, and host cells are also provided, as defined herein. A method for producing an antibody as defined herein is also provided. Disclosure includes combining the aspects and features described, except where such combination is clearly inadmissible or expressly prohibited. SUMMARY OF FIGURES
[0019] Instances and experiments illustrating the principles of revelation will now be discussed with reference to the attached figures in which:
[0020] Figure 1 shows parental IgG1-TM AZ Vk + AZ VH, (A) shows the binding of parental IgG1-TM AZ Vk + AZ antibody to HPB-ALL cells, which express human CD3 (hCD3+). (B) shows the binding of parental IgG1-TM anti-CD3 AZ Vk + AZ antibody to HSC-F cells, which express cynomolgus monkey CD3 (cyCD3+). (C) shows the binding of parental IgG1-TM anti-CD3 AZ Vk + AZ antibody to Jurkat hCD3+ cells. (D) shows the binding of parental IgG1-TM anti-CD3 AZ Vk + AZ antibody to Jurkat T cell receptor (TCR) knockout (KO) cells.
[0021] Figure 2 shows the binding of variants resulting from the mitigation of potential sequence imputabilities in CDR L1-2 and CDR H1-2 to CD3+ cells measured by flow cytometry. (A) shows the binding of the parental anti-CD3 antibody and variants to HPB-ALL cells, which express human CD3 (hCD3+). (B) shows the binding of the parental anti-CD3 antibody and AZ variants to HSCF cells, which express cynomolgus monkey CD3 (cyCD3+). (C) shows the binding of the parental anti-CD3 antibody and variants to Jurkat hCD3+ cells. (D) shows the Petition 870260111560, dated 10 / 29 / 2026, p. 13 / 219 9 / 92 Binding of parental anti-CD3 antibody and AZ variants to Jurkat knockout (KO) T cell receptor (TCR) cells.
[0022] Figure 3 shows the results of anti-CD3 variant profiling for CD3+ cell binding. Binding to (A) HPB-ALL (hCD3+) and (B) HSC-F (cyCD3+) cells was measured by flow cytometry.
[0023] Figure 4 shows the results of profiling anti-CD3 variants for EGFR+ cell toxicity. The cytotoxicity profiles of the EGFR-CD3 variant antibodies were evaluated by flow cytometry after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the variants based on AZ Vk 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0024] Figure 5 shows the results of anti-CD3 variant profiling for CD4+ T cell activation. CD4+ T cell activation profiles of EGFR-CD3 variant antibodies were evaluated by flow cytometry after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0025] Figure 6 shows the results of anti-CD3 variant profiling for CD8+ T cell activation. CD8+ T cell activation profiles of EGFR-CD3 variant antibodies were evaluated by flow cytometry after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0026] Figure 7 shows the results of profiling anti-CD3 variants for IL-6 release. The IL-6 cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay. Petition 870260111560, dated 10 / 29 / 2026, page 14 / 219 10 / 92 after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0027] Figure 8 shows the results of anti-CD3 variant profiling for TNF-α release. TNF-α cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0028] Figure 9 shows the results of anti-CD3 variant profiling for IFN-γ release. IFN-γ cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0029] Figure 10 shows the results of anti-CD3 variant profiling for IL-2 release. IL-2 cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0030] Figure 11 shows the results of profiling anti-CD3 variants for IL-10 release. The IL-10 cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+ NCI H358. The data that Petition 870260111560, dated 10 / 29 / 2026, page 15 / 219 11 / 92 representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ-based variants Vk 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0031] Figure 12 shows the results of anti-CD3 variant profiling for FasL release. FasL cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0032] Figure 13 shows the results of anti-CD3 variant profiling for granzyme A release. Granzyme A cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0033] Figure 14 shows the results of anti-CD3 variant profiling for granzyme B release. Granzyme B cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0034] Figure 15 shows the results of anti-CD3 variant profiling for IL-17A release. IL-17A cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Petition 870260111560, dated 10 / 29 / 2026, page 16 / 219 12 / 92 The data representing the variants based on AZ Vk 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0035] Figure 16 shows the results of anti-CD3 variant profiling for perforin release. The perforin cytokine release profiles of EGFR-CD3 variant antibodies were evaluated using the ProcartaPlex multiplex immunoassay after 24 hours of T cell exposure with EGFR+ NCI H358. Data representing the parental anti-CD3 variant appear in filled black circles. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray, respectively.
[0036] Figure 17 shows the EGFR+-dependent cytotoxicity and T cell activation for selected anti-CD3 variants. The cytotoxicity (A), CD4+ T cell activation (B), and CD8+ T cell activation (C) profiles of selected EGFR-CD3 variant antibodies were evaluated by flow cytometry after 24 hours of T cell exposure with EGFR+ MDA-MB-468. The results show EGFR-dependent responses.
[0037] Figure 18 shows that anti-CD3 variants exhibit cell activation. Reduced T cell count compared to parental anti-CD3 in the absence of EGFR+ cells. CD4+ (A) and CD8+ (B) T cell activation profiles were assessed by flow cytometry after 48 hours of exposure to immobilized EGFR-CD3 variant antibodies. Data representing the parental anti-CD3 variant are shown in filled black bars. Data representing the AZ Vk-based variants 17, 26, and 29 are shown in dark, medium, and light gray bars, respectively.
[0038] Figure 19 shows the kinetic measurements of anti-CD3 variants. The kinetic measurements of the soluble form of CD3 were obtained using an Octet384 instrument. The dissociation constants, KD, were calculated as a ratio of koff / kon from a non-linear fit of the data.
[0039] Figure 20 contains a schematic of DuetMab antibodies containing charge pairs. The HC hole on the left is linked by disulfide bonds through cysteines. Petition 870260111560, dated 10 / 29 / 2026, p. 17 / 219 13 / 92 native to a kappa LC and contains a pair of kappa charges (e.g., S183K / V133E), indicated by the minus (-) symbol on the kappa LC and the plus (+) symbol on the HC hole. The HC knob on the right is disulfide-linked through manipulated cysteines to the lambda LC and contains a pair of lambda charges, indicated by the plus (+) symbol on the lambda LC and the minus (-) symbol on the HC knob.
[0040] Figure 21 contains a schematic of the DuetMab '2+1' antibodies containing charge pairs. The HC knob on the right is disulfide-linked through manipulated cysteines to the lambda LC and contains a pair of lambda charges, indicated by the plus (+) symbol on the lambda LC and the minus (-) symbol on the HC knob. The CH1 and VH regions of that HC knob and lambda LC form a CD3 antigen-binding arm. The HC hole on the left is disulfide-linked via native cysteines to a kappa LC and contains a pair of kappa charges (e.g., S183K / V133E), indicated by the minus (-) symbol on the kappa LC and the plus (+) symbol on the HC hole.A third antigen-binding arm is fused from the amino-terminal of its CH1 to the C-terminal of the HC knob by a peptide linker. The CH1 of the third antigen-binding arm is disulfide-linked through native cysteines to a kappa LC and contains a pair of kappa charges. As indicated by the different shading, the first antigen-binding arm binds to a first epitope (CD3), and the second and third binding arms bind to a different second epitope.
[0041] Figure 22 contains a schematic of the trispecific 'TriMab' antibodies containing charge pairs. The HC knob on the right is disulfide-linked via manipulated cysteines to the lambda LC and contains a lambda charge pair, indicated by the plus (+) symbol on the lambda LC and the minus (-) symbol on the HC knob. The CH1 and VH region of that HC and lambda LC knob forms a first antigen-binding arm. The HC hole on the left is disulfide-linked via native cysteines to a kappa LC and contains a kappa charge pair, indicated by the minus (-) symbol on the kappa LC and the plus (+) symbol on the HC hole. The CH1 and VH region of that HC and kappa LC hole forms a second antigen-binding arm. Petition 870260111560, dated 10 / 29 / 2026, p. 18 / 219 14 / 92 A third antigen-binding arm is fused from the amino-terminal of its CH1 to the C-terminal of the HC knob by a peptide linker. The CH1 of the third antigen-binding arm is disulfide-linked via cysteines manipulated to a kappa LC and contains a pair of kappa charges, with charges opposite to the second antigen-binding arm – a negatively charged (-) amino acid residue in CH1 and a positively charged (+) amino acid residue in the kappa LC. As indicated by the different shading, the first antigen-binding arm (dark shading) binds to a first epitope, the second antigen-binding arm (light shading) binds to a second epitope, and the third binding arm (hatched shading) binds to a third epitope. DETAILED DESCRIPTION OF THE REVELATION
[0042] Aspects and instances of the present disclosure will now be discussed with reference to the accompanying figures. Other aspects and instances will be evident to those skilled in the art. All documents mentioned in this text are incorporated into the present invention by reference. Antibodies
[0043] The present disclosure relates to antibodies. The antibodies according to the present disclosure may be supplied in isolated form, in the sense of being free from contaminants, as antibodies capable of binding to other polypeptides and / or serum components.
[0044] The term antibody or antibody molecule describes a naturally occurring or partially or completely synthetically produced immunoglobulin. The antibody may be human or humanized. In some respects, the antibody is a monoclonal antibody. Examples of antibodies are immunoglobulin isotypes, such as immunoglobulin G (IgG), and their isotypic subclasses, such as IgG1, IgG2, IgG3, and IgG4, as well as fragments thereof.
[0045] The term antibody, as used herein, includes multispecific antibodies and antibody fragments. A multispecific antibody is an antibody that Petition 870260111560, dated 10 / 29 / 2026, page 19 / 219 15 / 92 comprises at least two antigen-binding domains, each capable of binding to a different target. Antibody fragments refer to a portion of the full-length antibody that exhibits binding to the relevant target molecule(s). Typically, an antibody fragment will contain the antigen-binding or variable region of the antigen.
[0046] An antibody is typically composed of two different types of polypeptide chains: one called a heavy chain and the other called a light chain. A naturally occurring monospecific antibody consists of two identical heavy chains and two identical light chains. The two heavy chains are typically linked together by disulfide bonds, and each heavy chain is typically linked to a light chain by a disulfide bond. The disulfide bonds linking the light and heavy chains are sometimes called interchain disulfide bonds, to distinguish them from the intrachain disulfide bonds that are present in individual heavy and light chain polypeptides.
[0047] The formation of disulfide bonds between cysteine residues occurs during the folding of many proteins that enter the secretory pathway. As the polypeptide chain folds, cysteines placed in close proximity can form covalent bonds during a process catalyzed by members of the disulfide isomerase protein family. The term disulfide bond or disulfide-linked, as used herein, refers to the single covalent bond formed from the coupling of thiol groups, especially cysteine residues. In some respects, the covalent bond between two cysteines is between the two sulfur atoms of each residue. However, depending on the environment, not all protein species may have a disulfide present at all times, for example, in the case of disulfide reduction.Thus, the term disulfide bond or disulfide-linked (whether native or manipulated), in some respects, also refers to the presence of two cysteine residues that are capable of forming a disulfide bond, regardless of whether or not they are actually linked at that individual point in time. Petition 870260111560, dated 10 / 29 / 2026, page 20 / 219 16 / 92
[0048] All light chains in natural antibodies are lambda λ or kappa κ light chains, which differ in terms of their amino acid sequence. Light chains are composed of a single constant light chain region (CL) and a single variable light chain region (VL). An example of an amino acid sequence for the lambda constant light chain region (CLλ) is provided as SEQ ID NO: 105 and an example of an amino acid sequence for the kappa constant light chain region (CLk) is provided as SEQ ID NO: 106. The light chains used in the antibodies described herein may be chimeric light chains, for example, containing both a CLλ and a VLk.
[0049] IgG heavy chains are composed of a variable heavy (VH) region and three constant heavy regions (CH1, CH2, and CH3), with an additional hinge region between CH1 and CH2. An example of an amino acid sequence of the CH1 region of IgG1 is provided as SEQ ID NO: 101. An example of an amino acid sequence of the CH2 region of IgG1 is provided as SEQ ID NO: 102. An example of an amino acid sequence of the CH3 region of IgG1 is provided as SEQ ID NO: 103. An example of a heavy chain amino acid sequence comprising a CH1, a hinge, a CH2, and a CH3 is provided as SEQ ID NO: 104.
[0050] Except where otherwise specified, amino acid residue positions in the constant domain, including amino acid sequence positions, substitutions, deletions, and insertions, as described herein, are numbered according to EU numbering (Edelman, 2007).
[0051] The light chain associates with VH and CH1 to form an antigen-binding arm, also called here the target-binding arm, and the variable domains in the antigen-binding arm interact to form the antigen-binding domain.
[0052] An antigen-binding domain describes the part of a molecule that binds to all or part of the target antigen and generally comprises six complementarity-determining regions (CDRs). Petition 870260111560, dated 10 / 29 / 2026, page 21 / 219 17 / 92 regions); three in the VH region: HCDR1, HCDR2, and HCDR3, and three in the VL region: LCDR1, LCDR2, and LCDR3. The six CDRs together define the paratope of the antigen-binding domain, which is the part of the antigen-binding domain that binds to the target antigen.
[0053] The VH and VL regions comprise framework regions (FRs) on each side of each CDR, which provide a framework for the CDRs. From the amino-terminus to the C-terminus, the VH regions comprise the following structure: N-terminus-[HFR1]-[HCDR1]-[HFR2]-[HCDR2]-[HFR3]-[HCDR3][HFR4]-C-terminus; and the VL regions comprise the following structure: N-terminus-[LFR1][LCDR1]-[LFR2]-[LCDR2]-[LFR3]-[LCDR3]-[LFR4]-C-terminus. Typically, the antigen-binding domain comprises the VH and VL regions.
[0054] An antigen-binding arm, as described herein, comprises the antigen-binding domain (e.g., the VH and VL regions) and also a CH1 and a constant light chain (i.e., at least one constant and one variable domain of each of the heavy and light chains), wherein the constant light chain is disulfide-linked to CH1. A monoclonal monospecific IgG antibody molecule contains two antigen-binding arms, each of which is capable of binding to the same target (i.e., it is bivalent for a single target).
[0055] Examples of antibody fragments include Fab, Fab', F(ab')2, Fd and Fv. Diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies are antibodies formed from these antibody fragments.
[0056] Traditionally, these fragments were derived through proteolytic digestion of intact antibodies using techniques known in the art. However, these fragments can now be directly produced by recombinant host cells. The Fab, Fv, and scFv antibody fragments can be expressed and secreted from E. coli, thus enabling the facilitated production of large quantities of these fragments. In one aspect, the antibody fragments can be isolated from antibody phage libraries. Petition 870260111560, dated 10 / 29 / 2026, page 22 / 219 18 / 92 discussed elsewhere here. Fab'-SH fragments can also be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments. F(ab')2 fragments can also be directly isolated from recombinant host cell culture. Other techniques for producing antibody fragments are known in the art. In certain respects, the antibodies provided here comprise a single-chain Fv fragment (scFv single-chain Fv) or other antigen-binding domain.
[0057] In some cases, the antibody fragments described here comprise domain antibodies, for example, antibodies containing the small functional antibody-binding units corresponding to the transportable region of the VH and VL chains of human antibodies. CD3 antigen-binding domain
[0058] The present disclosure provides antibodies comprising an antigen-binding domain that is capable of binding to a CD3 protein or a fragment thereof. These antigen-binding domains are also referred to herein as CD3 antigen-binding domains. In some cases, antibodies comprising antigen-binding domains bind monovalently to CD3 (e.g., the antibody contains only a single CD3 antigen-binding domain).
[0059] CD3 (cluster of differentiation 3) is a protein complex composed of four subunits: the CD3γ chain, the CD3δ chain, and two CD3ε chains. CD3 associates with the T cell receptor and the ζ chain to generate an activation signal in T lymphocytes.
[0060] The CD3 antigen-binding domain comprises the CDRs of an antibody that is capable of binding to CD3. In some cases, the CD3 antigen-binding domain comprises a VH region and / or a VL region that is, or has at least 70% identity with, the VH and / or VL region of an antibody that binds to CD3 as exemplified here. Petition 870260111560, dated 10 / 29 / 2026, page 23 / 219 19 / 92
[0061] In some cases, the CD3 antigen-binding domain comprises a VH region according to any one of (1) to (9) below:
[0062] An antibody comprising an antigen-binding domain capable of binding to a CD3 protein or a fragment thereof, wherein the CD3 antigen-binding domain comprises a variable heavy chain (VH) region according to any of the following: (1) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:90; HCDR2 with the amino acid sequence SEQ ID NO: 91;e HCDR3 with amino acid sequence SEQ ID NO:92, (2) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:82; HCDR2 with the amino acid sequence SEQ ID NO: 83;e HCDR3 with amino acid sequence SEQ ID NO:84, (3) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:78; HCDR2 with the amino acid sequence SEQ ID NO: 79;e HCDR3 with amino acid sequence SEQ ID NO:80, (4) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:66; HCDR2 with the amino acid sequence SEQ ID NO: 67;e HCDR3 with the amino acid sequence SEQ ID NO:68, (5) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:70; HCDR2 with the amino acid sequence SEQ ID NO: 71;e HCDR3 with the amino acid sequence SEQ ID NO:72, (6) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence SEQ ID NO:74; HCDR2 with the amino acid sequence SEQ ID NO: 75;e Petition 870260111560, dated 10 / 29 / 2026, p. 24 / 219 20 / 92 HCDR3 with amino acid sequence SEQ ID NO: 76, (7) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:86; HCDR2 with the amino acid sequence SEQ ID NO: 87;e HCDR3 with the amino acid sequence SEQ ID NO:88, (8) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence SEQ ID NO:94; HCDR2 with the amino acid sequence SEQ ID NO: 95;e HCDR3 with the amino acid sequence SEQ ID NO: 96,e (9) a VH region comprising the following CDRs: HCDR1 with the amino acid sequence SEQ ID NO:98; HCDR2 with the amino acid sequence SEQ ID NO: 99;e HCDR3 with the amino acid sequence SEQ ID NO:100,
[0063] In some cases, the CD3 antigen-binding domain comprises a VL region according to any one of (1) to (3) below: (10) a VL region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:46; HCDR2 with the amino acid sequence SEQ ID NO: 47;e HCDR3 with amino acid sequence SEQ ID NO:48, (11) a VL region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:58; HCDR2 with the amino acid sequence SEQ ID NO: 59;e HCDR3 with the amino acid sequence of SEQ ID NO: 60,e (12) a VL region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:62; HCDR2 with the amino acid sequence of SEQ ID NO: 63;e HCDR3 with the amino acid sequence SEQ ID NO:64.
[0064] In some cases, the CD3 antigen-binding domain comprises a VH region according to any one of (1) to (9) and a VL region of Petition 870260111560, dated 10 / 29 / 2026, page 25 / 219 21 / 92 in accordance with any one of (10) to (12) above. For example, the CD3 antigen-binding domain may comprise: a VH region comprising the CDRs according to (1) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (2) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (3) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (4) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (5) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (6) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (7) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (8) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (9) and a VL region comprising the CDRs according to (10); a VH region comprising the CDRs according to (1) and a VL region comprising the CDRs according to (11); a VH region comprising the CDRs according to (2) and a VL region comprising the CDRs according to (11); a VH region comprising the CDRs according to (3) and a VL region comprising the CDRs according to (11); a VH region comprising the CDRs according to (4) and a VL region comprising the CDRs according to (11); Petition 870260111560, dated 10 / 29 / 2026, page 26 / 219 22 / 92 a VH region comprising the CDRs according to (5) and a VL region comprising the CDRs according to (11); a VH region comprising the CDRs according to (6) and a VL region comprising the CDRs according to (11); a VH region comprising the CDRs according to (7) and a VL region comprising the CDRs according to (11); a VH region comprising the CDRs according to (8) and a VL region comprising the CDRs according to (11); a VH region comprising the CDRs according to (9) and a VL region comprising the CDRs according to (11); a VH region comprising the CDRs according to (1) and a VL region comprising the CDRs according to (12); a VH region comprising the CDRs according to (2) and a VL region comprising the CDRs according to (12); a VH region comprising the CDRs according to (3) and a VL region comprising the CDRs according to (12); a VH region comprising the CDRs according to (4) and a VL region comprising the CDRs according to (12); a VH region comprising the CDRs according to (5) and a VL region comprising the CDRs according to (12); a VH region comprising the CDRs according to (6) and a VL region comprising the CDRs according to (12); a VH region comprising the CDRs according to (7) and a VL region comprising the CDRs according to (12); a VH region comprising the CDRs according to (8) and a VL region comprising the CDRs according to (12); or a VH region comprising the CDRs according to (9) and a VL region comprising the CDRs according to (12). Petition 870260111560, dated 10 / 29 / 2026, page 27 / 219 23 / 92
[0065] In some cases, the CD3 antigen-binding domain does not comprise a VH region comprising CDRs according to (1) and a VL region comprising CDRs according to (12).
[0066] In some cases, the CD3 antigen-binding domain comprises: (13) a VH region comprising the CDRs according to (3) and a VL region comprising the CDRs according to (12); (14) a VH region comprising the CDRs according to (1) and a VL region comprising the CDRs according to (10); or (15) a VH region comprising the CDRs according to (2) and a VL region comprising the CDRs according to (10).
[0067] In some cases, the CD3 antigen-binding domain comprises a VH region according to any one of (16) to (24) below: (16) a VH region comprising the CDRs according to (1) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 89; (17) a VH region comprising the CDRs according to (2) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 81; (18) a VH region comprising the CDRs according to (3) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 77; (19) a VH region comprising the CDRs according to (4) and comprising an amino acid sequence with at least 70% identity Petition 870260111560, dated 10 / 29 / 2026, p. 28 / 219 24 / 92 sequence, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 65; (20) a VH region comprising the CDRs according to (5) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 69; (21) a VH region comprising the CDRs according to (6) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 73; (22) a VH region comprising the CDRs according to (7) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 85; (23) a VH region comprising the CDRs according to (8) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 93; and (24) a VH region comprising the CDRs according to (9) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 97. Petition 870260111560, dated 10 / 29 / 2026, page 29 / 219 25 / 92
[0068] In some cases, the CD3 antigen-binding domain comprises a VL region according to any one of (25) to (27) below: (25) a VL region comprising the CDRs according to (10) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 45; (26) a VL region comprising the CDRs according to (11) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 57; and (27) a VL region comprising the CDRs according to (12) and comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 61;
[0069] In some cases, the CD3 antigen-binding domain comprises a VH region according to any one of (16) to (24) and a VL region according to any one of (25) to (27) above. For example, the CD3 antigen-binding domain may comprise: a VH region according to (16) and a VL region according to (25); a VH region according to (17) and a VL region according to (25); a VH region according to (18) and a VL region according to (25); a VH region according to (19) and a VL region according to (25); a VH region according to (20) and a VL region according to (25); a VH region according to (21) and a VL region according to (25); a VH region according to (22) and a VL region according to (25); a VH region according to (23) and a VL region according to (25); Petition 870260111560, dated 10 / 29 / 2026, page 30 / 219 26 / 92 a VH region according to (24) and a VL region according to (25); a VH region according to (16) and a VL region according to (26); a VH region according to (17) and a VL region according to (26); a VH region according to (18) and a VL region according to (26); a VH region according to (19) and a VL region according to (26); a VH region according to (20) and a VL region according to (26); a VH region according to (21) and a VL region according to (26); a VH region according to (22) and a VL region according to (26); a VH region according to (23) and a VL region according to (26); a VH region according to (24) and a VL region according to (26); a VH region according to (16) and a VL region according to (27); a VH region according to (17) and a VL region according to (27); a VH region according to (18) and a VL region according to (27); a VH region according to (19) and a VL region according to (27); a VH region according to (20) and a VL region according to (27); a VH region according to (21) and a VL region according to (27); a VH region according to (22) and a VL region according to (27); a VH region according to (23) and a VL region according to (27); or a VH region according to (24) and a VL region according to (27).
[0070] In some cases, the CD3 antigen-binding domain does not comprise a VH region according to (16) and a VL region according to (27).
[0071] In some cases, the CD3 antigen-binding domain comprises: (28) a VH region according to (18) and a VL region according to (27); (29) a VH region according to (16) and a VL region according to (25); or (30) a VH region according to (17) and a VL region according to (25). Petition 870260111560, dated 10 / 29 / 2026, page 31 / 219 27 / 92
[0072] The antibodies described herein may exhibit reduced toxicity due to lower binding affinity, while maintaining T cell activation, thus ensuring T cell engagement. The antibody described herein can be characterized by a CD3 antigen-binding domain with a specific affinity for CD3. The binding affinity of an antibody molecule to a cognate antigen, such as human CD3 (e.g., recombinant human CD3εδ, such as that available from Acro Biosystems, CDD-H82W6), can be determined by surface plasmon resonance (SPR), using Octet or Biacore analysis, for example. Binding affinity can be determined using an antibody, for example, as part of a multispecific antibody molecule comprising the CD3 antigen-binding domain and another antigen-binding domain. Alternatively, binding affinity can be determined using an antibody that is monospecific for CD3.
[0073] Binding affinity is typically measured by Kd (the equilibrium dissociation constant between the antigen-binding domain and its antigen). As is well understood, the smaller the Kd value, the higher the binding affinity of the antigen-binding domain. For example, an antigen-binding domain that binds to a target with a Kd of 10 nM would be considered to bind said target with a higher affinity than an antigen-binding domain that binds to the same target with a Kd of 100 nM.
[0074] In some cases, the CD3 antigen-binding domain binds to human CD3 with an affinity of Kd equal to or greater than 1 x 108M, equal to or greater than 9 x 107M, equal to or greater than 8 x 107M. In some cases, the CD3 antigen-binding domain binds to human CD3 with an affinity of Kd between 1 x 10⁸ M and 1 x 10⁶, between 9 x 10⁷ M and 1 x 10⁶, or between 8 x 10⁷ M and 1 x 10⁶. Optionally, Kd is measured using surface plasmon resonance, for example, using Octet analysis as described in the examples. Petition 870260111560, dated 10 / 29 / 2026, p. 32 / 219 28 / 92
[0075] The CD3 antigen-binding domain can bind to human CD3 with an affinity that is similar to that of an antigen-binding domain according to (28), (29) or (30) as set out above. For example, the CD3 antigen-binding domain can bind to human CD3 with an affinity with a Kd that is less than 5 times different, less than 4 times different, less than 3 times different, less than 2 times different, less than 1 time different or less than 0.5 times different from an antigen-binding domain according to (28), (29) or (30) as set out above.
[0076] The CD3 antigen-binding domain can be classified as being able to bind specifically to CD3. The term specific can refer to the situation where the antigen-binding domain will not show any significant binding to molecules other than its specific binding partner(s), here CD3. These molecules are called non-target molecules. The term specific is also applicable when the antibody molecule is specific for specific epitopes, such as epitopes on CD3, which are carried by various antigens, in which case the antibody molecule will be able to bind to the various antigens carrying the epitope.
[0077] In some cases, the antigen-binding domain is considered to be CD3 shows no significant binding to a non-target molecule if the extent of binding to a non-target molecule is less than about 10% of the antibody binding to the target, as measured, for example, by ELISA, SPR, Bio-Layer Interferometry (BLI), Microscale Thermophoresis (MST), or radioimmunoassay (RIA). Alternatively, binding specificity can be reflected in terms of binding affinity, where the CD3 antigen-binding domain described here binds to CD3 with an affinity that is at least 0.1 order of magnitude greater than the affinity for another non-target molecule. In some cases, the CD3 antigen-binding domain described here binds to CD3 with an affinity that is Petition 870260111560, dated 10 / 29 / 2026, p. 33 / 219 29 / 92 one of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5 or 2.0 orders of magnitude greater than the affinity for another non-target molecule.
[0078] The CD3 antigen-binding domain can further be classified according to its ability to induce T cell activation. Methods for measuring T cell activation are well known in the art. For example, T cell activation can be assessed by measuring the upregulation of activation markers such as CD69 and / or CD25 in CD4+ and / or CD8+ T cells using flow cytometry. CD69 is a membrane-bound type II C-lectin receptor and is an early activation marker of T cell activation due to its rapid appearance on the plasma membrane surface after T cell activation (Cibrián et al., 2017). CD25 is a component of the IL-2 receptor, important in T cell proliferation, and is an important late activation marker in T cell proliferation and activation, and upregulation of CD25 on the cell surface indicates late T cell activation.Alternative methods of measuring T cell activation are being considered, such as measuring T cell proliferation or measuring the production of effector cytokines (e.g., IFN-γ and TNF-α) (Zappasodi, et al., 2020).
[0079] Consequently, T cell activation can be measured by calculating the percentage of CD4+ T cells and / or CD8+ T cells that are positive for CD69 and / or CD25 using flow cytometry, as was done in the examples. For example, an antigen-binding domain that induces upregulation of CD69 and CD25 in 20% of CD4+ T cells decreased T cell activity compared to an antigen-binding domain that induces upregulation of CD69 and CD25 in 80% of CD4+ T cells, as measured by flow cytometry.
[0080] As described herein, multispecific antibodies that bind to a target and CD3 aim to induce T cell activation only after engagement of a target cell (non-T cell) and a T cell. Off-target T cell activity can occur when the multispecific antibody induces T cell activation without Petition 870260111560, dated 10 / 29 / 2026, page 34 / 219 30 / 92 engagement of a target cell. Off-target T cell activation can be measured using a multispecific antibody molecule comprising the CD3 antigen-binding domain and another antigen-binding domain that binds to a different target antigen (e.g., a tumor-associated antigen (TAA)-binding domain) in a T cell activation assay in which cells expressing the target antigen are absent.
[0081] In some cases, the CD3 antigen-binding domain described here exhibits reduced off-target T cell activity compared to a control antigen-binding domain with a VH domain sequence shown as SEQ ID NO: 5 and a VL domain sequence shown as SEQ ID NO: 1. In some cases, the CD3 antigen-binding domain described here exhibits off-target T cell activity that is at least 2 times, at least 3 times, or at least 4 times lower compared to a control antigen-binding domain with a VH domain sequence shown as SEQ ID NO: 5 and a VL domain sequence shown as SEQ ID NO: 1. Off-target T cell activation can be determined using the antibody in a T cell activation assay in the absence of engagement with a target cell.In some cases, off-target T cell activation is determined by calculating the percentage of CD4+ T cells and / or CD8+ T cells that are positive for CD69 and / or CD25 using flow cytometry, in the absence of target cells expressing a target antigen to which the antibody is able to bind.
[0082] In some cases, the CD3 antigen-binding domain described here exhibits T cell activity measured by cytokine release from CD4+ and / or CD8+ T cells after CD3 binding, with T cell activity being reduced compared to a parental anti-CD3 control antibody. Cytokines can be selected from the group consisting of: IL-6, TNF-α, IFN-γ, IL-10, FasL, granzyme A, granzyme B, IL-17A, and perforin. Methods for measuring cytokine release are well known in the art and include, for example, measuring cytokine concentrations in the supernatants of a T cell culture using Petition 870260111560, dated 10 / 29 / 2026, page 35 / 219 31 / 92 an immunoassay, such as an ELISA. It is beneficial to keep cytokine release, particularly pro-inflammatory cytokines, under control after T cell activation, as it reduces the risk of cytokine release syndrome (CRS).
[0083] Hyperactivation of immune cells, such as T cells, can lead to CRS, which is a serious condition characterized by the hypersecretion of pro-inflammatory cytokines. In some cases, the antibody described here exhibits reduced cytotoxicity compared to a parental anti-CD3 control antibody. Assays to measure cytotoxicity may include measuring cell death by flow cytometry using propidium iodide (Crowley et al., 2016) or dyes that covalently bind to free amines on the surface and inside cells (such as CellTrace™). Multispecific antibodies
[0084] As mentioned above, CD3 antigen-binding domains are useful when used in a multispecific antibody format. For example, a multispecific antibody may contain a CD3 antigen-binding domain as described herein and a target antigen-binding domain capable of binding to a non-CD3 target. The target antigen-binding domain may be capable of binding to a tumor-associated antigen (TAA). These multispecific antibodies can be used for simultaneous binding to TAA expressed on cancer cells and CD3 on a T cell, thus forcing a temporary interaction between the target cell and the T cell, causing cross-linking, T cell activation, and subsequent antigen-dependent killing of the target cell by T cells.
[0085] In some cases, the antibody comprises a CD3 antigen-binding domain and a target antigen-binding domain. In some cases, the antibody additionally comprises an antigen-binding domain that is capable of binding to a TAA (also referred to here as a TAA antigen-binding domain). The antibody may be capable of monovalently binding to CD3 and Petition 870260111560, dated 10 / 29 / 2026, p. 36 / 219 32 / 92 monovalently to TAA (for example, the antibody comprises a CD3 antigen-binding domain and a TAA antigen-binding domain).
[0086] Examples of TAAs include AFP, anb3 (vitronectin receptor), anb6, B-cell maturation agent (BCMA), CA125 (MUC16), CD4, CD20, CD22, CD33, CD52, CD56, CD66e, CD80, CD140b, CD227 (MUC1), EGFR (HER1), EpCAM, ganglioside GD3, HER2, prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), CD5, CD19, CD21, CD25, CD37, CD30, CD33, CD45, HLA-DR, anti-idiotype, carcinoembryonic antigen (CEA), for example, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). cell adhesion molecule 5), TAG-72, folate-binding protein, A33, G250, ferritin, glycolipids such as gangliosides, carbohydrates such as CA-125, IL-2 receptor, fibroblast activation protein (FAP), IGF1R, B7H3, B7H4, PD-L1, CD200, EphA2,c-Met and mesothelin or variants thereof. In some respects, TAAs include EGFR, HER2, STEAP2, GPC3 and c-Met.
[0087] In some cases, the antibody comprises a CD3 antigen-binding domain and a CD8 antigen-binding domain. For example, the antibody may comprise a CD3 antigen-binding domain, a TAA antigen-binding domain, and a CD8 antigen-binding domain.
[0088] CD8 (group of differentiation 8) is a dimer consisting of a pair of CD8 chains. The most common form of CD8 is composed of a CD8-α and a CD8-β chain. CD8 serves as the co-receptor on MCHI-restricted T cells and acts to increase the antigen sensitivity of CD8+ T cells by binding to a largely invariant region of MCHI at a site distinct from where the T cell receptor binds. Without adhering to theory, it is believed that including an antigen-binding domain capable of binding to CD8 in the multispecific antibody makes preferential activation of CD8+ T cells possible, which may provide superior therapeutic efficacy. Petition 870260111560, dated 10 / 29 / 2026, p. 37 / 219 33 / 92
[0089] In some cases, the multispecific antibody is in a '2+1' format. In the '2+1 format', the antibody contains an antigen-binding domain that binds monovalently to a first epitope and two other antigen-binding domains that bind bivalently to a second epitope, where the second epitope is different from the first epitope. The 2+1 format of multispecific antibodies is well suited for CD3 binding, as the goal is to bind only monovalently to the CD3 protein, so that the T cell receptor is only cross-linked and activated after target cell binding. Consequently, in some cases, the antibody comprises the CD3 antigen-binding domain described here and two target antigen-binding domains that are capable of binding to the same target (e.g., a TAA).
[0090] In the '2 + 1' format, one of the two target antigen-binding domains is fused to any of the other antigen-binding domains present in the antibody, typically via a peptide linker. Suitable peptide linkers are known in the art and may consist of 5 to 100 amino acids, 5 to 50 amino acids, 5 to 25 amino acids, or 5 to 15 amino acids. Peptide linkers are formed primarily from glycine and serine amino acid residues and may comprise the amino acid sequences GGGGS (SEQ ID NO: 113) or SGGGGS (SEQ ID NO: 114). In one aspect, the peptide linker comprises or consists of (GGGGS)2 (SEQ ID NO: 115). In some cases, one of the target antigen-binding domains is fused (e.g., via a peptide linker) to the CD3 antigen-binding domain.
[0091] Multispecific antibodies comprising a CD8 antigen-binding region in addition to the antigen-binding arms of the bispecific '2+1' antibody are further described herein. These antibodies may be a tetravalent trispecific antibody: one CD3 antigen-binding domain binds monovalently to CD3, two target antigen-binding domains bind bivalently to a target (e.g., a TAA), while the CD8 antigen-binding domain (e.g., VHH) binds monovalently to CD8. Petition 870260111560, dated 10 / 29 / 2026, p. 38 / 219 34 / 92
[0092] In some cases, the CD8 antigen-binding domain is a single-domain antibody, such as a variable heavy chain (VH) domain lacking a CH1 and a light chain. The variable heavy chain domain derived from a heavy chain antibody that is naturally lacking a light chain is called VHH here to distinguish it from the conventional VH of a four-chain immunoglobulin. This VHH molecule can be derived from antibodies produced in camelid species, such as camels, alpacas, dromedaries, llamas, and guanacos. Different camelid species can also produce heavy chain antibodies that are naturally lacking a light chain, and these VHHs are also covered.
[0093] Similar to other non-human antibody fragments, the amino acid sequence of camelidae VHH can be recombinantly altered to obtain a sequence that more closely resembles a human sequence, i.e., humanized, thus reducing the antigenicity of camelidae VHH for humans. In addition, essential elements derived from camelidae VHH can also be transferred to the human VH domain to obtain a camelized human VH domain.
[0094] The CD8 antigen-binding domain (e.g., VHH) can be fused to any of the other antigen-binding domains present in the antibody, typically via a peptide linker. Suitable peptide linkers are known in the art and may consist of 5 to 100 amino acids, 5 to 50 amino acids, 5 to 25 amino acids, or 5 to 15 amino acids. Peptide linkers are formed primarily from glycine and serine amino acid residues and may comprise the amino acid sequences GGGGS (SEQ ID NO: 113) or SGGGGS (SEQ ID NO: 114). In one example, the peptide linker comprises or consists of (GGGGS)2 (SEQ ID NO: 115). In some cases, the CD8 antigen-binding domain is fused to one of the target antigen-binding domains. Petition 870260111560, dated 10 / 29 / 2026, page 39 / 219 35 / 92
[0095] In some respects, the CD8 antigen-binding domain (e.g., VHH) comprises the following complementarity-determining regions (CDRs): I. HCDR1 with the amino acid sequence SEQ ID NO: 109, 116 or 117; ii. HCDR2 with the amino acid sequence SEQ ID NO: 110; iii. HCDR3 with the amino acid sequence of SEQ ID NO: 111;
[0096] In some respects, the first antigen-binding arm comprises a VH region comprising an amino acid sequence with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 112, 118, 119 or 120.
[0097] The VHH proteins of SEQ ID NOs: 118 to 120 are derived from SEQ ID NO: 112, which have been modified to remove deamidation sites, including in the CDR1 sequence (see the modified CDR1 sequences of SEQ ID NOs: 116 and 117, which are derived from SEQ ID NO: 109). Thus, these modified VHHs may exhibit improved stability compared to the original VHH of SEQ ID NO: 112.
[0098] Multispecific antibodies are additionally described herein, which are trivalent and trispecific antibodies. In this format, the antibody contains three antigen-binding domains, each of which binds monovalently to a different epitope. Consequently, in some cases, the antibody comprises the CD3 antigen-binding domain described herein, the target antigen-binding domain (e.g., TAA), and a third antigen-binding domain. The third antigen-binding domain may be a CD8 antigen-binding domain or it may be a target antigen-binding domain (e.g., TAA) that binds to a different target (e.g., TAA) than the target antigen-binding domain. In this trispecific format, each antigen-binding domain comprises a Petition 870260111560, dated 10 / 29 / 2026, page 40 / 219 36 / 92 light chain, a VH and a CH1 (that is, at least one constant and one variable domain of each light chain), wherein the light chain is linked by disulfides to the CH1 (that is, each antigen-binding domain is an antigen-binding arm).
[0099] In some respects, one of the antigen-binding arms of an Antigen 1 / Antigen 2 / CD3 TriMab is capable of binding to an epitope on Antigen 1 or Antigen 2 that does not induce cellular cytotoxicity. In some respects, the Antigen 1-binding arm of an Antigen 1 / Antigen 2 / CD3 TriMab will induce cellular cytotoxicity, and the Antigen 2-binding arm will act as a docking arm without the capacity to induce cellular cytotoxicity in cells expressing only Antigen 2. The inability of the docking arm to induce cellular cytotoxicity may be due, for example, to binding to a distal membrane epitope that prevents the ability to form an active immunological synapse.
[0100] The recently identified lambda charge pairs can be used in conjunction with kappa charge pairs to produce trispecific antibodies containing three different antigen-binding arms. In particular, it has been recognized that: - Efficient pairing of a first antigen-binding arm can be achieved by using a lambda charge pair between the CH1 and CLλ of the first antigen-binding arm (e.g., the CD3 antigen-binding arm described here); - Efficient pairing of a second antigen-binding arm can be achieved using a kappa charge pair between the CH1 and CLk of the second antigen-binding arm (e.g., the target antigen-binding arm described here); and Petition 870260111560, dated 10 / 29 / 2026, page 41 / 219 37 / 92 - Efficient pairing of a third antigen-binding arm can be achieved by using a pair of kappa charges between the CH1 and CLk of the third antigen-binding arm (e.g., a CD8 target antigen-binding arm or a target antigen-binding domain (e.g., TAA) that binds to a different target than the second antigen-binding arm), where the charged amino acid residues are in the opposite arrangement to that of the second antigen-binding arm.
[0101] Having the kappa charge pairs in the opposite arrangement to that of the second antigen-binding arm means that if the kappa charge pair of the second antigen-binding arm contains a positively charged amino acid residue in CH1 and a negatively charged amino acid residue in CLk, then the kappa charge pair of the third antigen-binding arm contains a negatively charged residue in CH1 and a positively charged amino acid residue in CLk. Constant regions
[0102] As described herein, antigen-binding domains (e.g., the VH and VL regions defined above) may additionally comprise constant domains of a heavy and a light chain. An antigen-binding domain additionally comprising a CH1 and a constant light chain, wherein the constant light chain is disulfide-linked to the CH1, is also referred to herein as an antigen-binding arm or a Fab region.
[0103] In some cases, the antibody described herein comprises one or more constant regions of immunoglobulin heavy chain (HC). In some cases, the HC is, or is derived from, the constant sequence of heavy chain of an IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgA (e.g., IgA1, IgA2), IgD, IgE, or IgM.
[0104] IgG heavy chains are composed of a variable heavy (VH) region and three constant heavy regions (CH1, CH2, and CH3), with an additional hinge region between CH1 and CH2. An example of the amino acid sequence of the CH1 region of IgG1 is provided as SEQ ID NO: 101. An example Petition 870260111560, dated 10 / 29 / 2026, p. 42 / 219 38 / 92 of an amino acid sequence of CH2 from IgG1 is provided as SEQ ID NO: 102. An example of an amino acid sequence of CH3 from IgG1 is provided as SEQ ID NO: 103. An example of a heavy chain amino acid sequence comprising a CH1, a hinge, a CH2 and a CH3 is provided as SEQ ID NO: 104.
[0105] Each antigen-binding domain may additionally comprise additional heavy chain regions, that is, one or more of the following: CH1, hinge, CH2, and CH3. In some cases, the antigen-binding domain comprises a complete heavy chain (that is, a VH, a CH1, a hinge, a CH2, and a CH3).
[0106] In some cases, the antigen-binding domain comprises a CH1 region with an amino acid sequence that has at least 70% sequence identity or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 101.
[0107] In some cases, the antigen-binding domain comprises a CH2 region with an amino acid sequence that has at least 70% sequence identity or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 102.
[0108] In some cases, the antigen-binding domain comprises a CH3 region with an amino acid sequence that has at least 70% sequence identity or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 103.
[0109] In some cases, the antigen-binding domain comprises a constant heavy chain region with an amino acid sequence having at least 70% sequence identity or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% Petition 870260111560, dated 10 / 29 / 2026, page 43 / 219 39 / 92 or 100% sequence identity with the amino acid sequence of SEQ ID NO: 104.
[0110] In some cases, the antibody described here comprises a constant region of immunoglobulin light chain (LC) or a fragment thereof. In some cases, the CL region comprises a constant lambda region (CLÃ), for example, with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 105. In some cases, the CL region comprises a constant kappa region (CLk), for example, with at least 70% sequence identity, or at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 106.
[0111] In some cases, the antibody comprises a complete light chain comprising or consisting of a VL region as described herein and a CL region as described herein. For example, the antibody may comprise a heavy chain containing the VL region of a CD3 antigen-binding domain described herein and a CL region as described herein (e.g., a CLÃ or CLk region).
[0112] The CH, CL, heavy chain and / or light chain of the antibodies described herein may comprise one or more modifications, for example, to abolish or reduce the effector functions of Fc, to promote the formation of a heterodimeric antibody molecule, to increase the effectiveness of cognate heavy and light chain pairing and / or to assist in conjugate formation, as described in more detail below. Load pairs
[0113] In some cases, an antigen-binding arm (Fab region) of the antibody described herein comprises a pair of charges, one located in a light chain region (e.g., constant light chain region) and the other in a heavy chain region (e.g., constant heavy chain 1 (CH1) region) of an antigen-binding arm, located in positions intended to promote the Petition 870260111560, dated 10 / 29 / 2026, p. 44 / 219 40 / 92 Association of light and heavy chains. A lambda charge pair is understood to be a pair of charges in which a positively or negatively charged amino acid residue is located on a lambda light chain. A kappa charge pair is understood to be a pair of charges in which a positively or negatively charged amino acid residue on the light chain is located on a kappa light chain.
[0114] Without adhering to theory, it is believed that oppositely charged amino acid residues in the charge pair increase the attraction of the heavy chain for the light chain in an antigen-binding arm, thus promoting the formation of the antigen-binding arm with the correct heavy and light chain.
[0115] In some respects, at least one of the amino acid residues in the charge pair has been manipulated in the antigen-binding arm (i.e., at least one amino acid residue in the pair is not a wild-type amino acid residue). In some respects, both amino acid residues in the charge pair are manipulated in the antigen-binding arm (i.e., both amino acid residues in the pair are not wild-type amino acid residues).
[0116] The amino acid residues of the charge pair are typically naturally occurring. Naturally occurring positively charged amino acid residues according to the present disclosure include arginine, lysine, and histidine. Naturally occurring negatively charged amino acid residues according to the present disclosure include glutamic acid, serine, threonine, and aspartic acid. Although serine and threonine are often described in the art as uncharged, they have an isoelectric point below 6 and are therefore partially negatively charged at neutral pH. For the purposes of the charge pairs described herein, serine and threonine are examples of negatively charged amino acid residues (along with glutamic acid and aspartic acid).
[0117] Thus, a charge pair may comprise a positively charged amino acid residue selected from arginine, lysine, or histidine situated at one of the positions in the charge pair and a charged amino acid residue Petition 870260111560, dated 10 / 29 / 2026, page 45 / 219 41 / 92 negatively selected from among aspartic acid, glutamic acid, serine, or threonine located at the other position in the charge pair. For example, the charge pair may comprise any of the following pairs of amino acid residues: arginine and aspartic acid; arginine and glutamic acid; arginine and serine; arginine and threonine; lysine and aspartic acid; lysine and glutamic acid; lysine and serine; lysine and threonine; histidine and aspartic acid; histidine and glutamic acid; histidine and serine; and histidine and threonine
[0118] In some cases, the positively charged amino acid residue in the charge pair is located on the light chain and the negatively charged amino acid residue in the charge pair is located on the heavy chain. In other cases, the negatively charged amino acid residue is located on the light chain and the positively charged amino acid residue in the charge pair is located on the heavy chain. Charge pairs can be introduced in various positions to improve the pairing of the correct light and heavy chains in the antigen-binding arm.
[0119] In some cases, the antigen-binding arm (e.g., CD3 antigen-binding arm) comprises a pair of lambda charges. As demonstrated here, amino acid residues at the interface between a lambda LC and a lambda HC have been identified where charge pairs could be introduced, demonstrating that the introduction of these lambda charge pairs could advantageously improve chain pairing beyond what was achieved in a format Petition 870260111560, dated 10 / 29 / 2026, page 46 / 219 42 / 92 of the previous antibody lacking a lambda charge pair. In some cases, the lambda charge pair comprises a positively or negatively charged amino acid residue at position 117, 119, 134, 136, or 178 of the lambda constant region of the light chain (CLA). In some aspects, the lambda charge pair comprises a positively or negatively charged amino acid residue at position 141, 185, 128, 145, 183, 185, 173, or 187 of CH1, the numbering being in accordance with EU numbering.
[0120] In some cases, the lambda load pair is located in one or more of the following pairs of positions: (i) position 117 in CLA and position 141 in CH1; (ii) position 117 in CLA and position 185 in CH1; (iii) position 119 in CLA and position 128 in CH1; (iv) position 134 in CLA and position 128 in CH1; (v) position 134 in CLA and position 145 in CH1; (vi) position 134 in CLA and position 183 in CH1; (vii) position 136 in CLA and position 185 in CH1; (viii) position 178 in CLA and position 173 in CH1; and (ix) position 117 in CLA and position 187 in CH1.
[0121] In some cases, the lambda charge pair is located in the charge pair situated at position 117 in CLA and at position 141 in CH1. For example, the lambda charge pair can be selected from the following list: a. arginine at position 117 of CLA and aspartic acid at position 141 of CH1; b. arginine at position 117 of CLA and glutamic acid at position 141 of CH1; c. arginine at position 117 of CLA and serine at position 141 of CH1; d. arginine at position 117 of CLA and threonine at position 141 of CH1; e. lysine at position 117 of CLA and aspartic acid at position 141 of CH1; f. lysine at position 117 of CLA and glutamic acid at position 141 of CH1; Petition 870260111560, dated 10 / 29 / 2026, page 47 / 219 43 / 92 g. lysine at position 117 of CLλ and serine at position 141 of CH1; and h. lysine at position 117 of CLλ and threonine at position 141 of CH1.
[0122] In some cases, the lambda load pair is selected from any one of a. to f. in the list above. In some respects, the lambda load pair is selected from any one of a. to e. in the list above. In some respects, the lambda load pair is selected from any one of a., b., and e. in the list above. In some respects, the lambda load pair is a.
[0123] In some cases, the lambda charge pair is located in the charge pair situated at position 117 in CLλ and at position 185 in CH1. For example, the lambda charge pair can be selected from the following list: a. arginine at position 117 of CLλ and aspartic acid at position 185 of CH1; b. arginine at position 117 of CLλ and glutamic acid at position 185 of CH1; c. arginine at position 117 of CLλ and serine at position 185 of CH1; d. arginine at position 117 of CLλ and threonine at position 185 of CH1; e. lysine at position 117 of CLλ and aspartic acid at position 185 of CH1; f. lysine at position 117 of CLÀ and glutamic acid at position 185 of CH1; g. lysine at position 117 of CLÀ and serine at position 185 of CH1; and h. lysine at position 117 of CLÀ and threonine at position 185 of CH1.
[0124] In some cases, the lambda charge pair is located in the charge pair situated at position 119 in CLÀ and at position 128 in CH1. For example, the lambda charge pair can be selected from the following list: a. arginine at position 119 of CL1 and aspartic acid at position 128 of CH1; b. arginine at position 119 of CL1 and glutamic acid at position 128 of CH1; c. arginine at position 119 of CL1 and serine at position 128 of CH1; d. arginine at position 119 of CL1 and threonine at position 128 of CH1; Petition 870260111560, dated 10 / 29 / 2026, page 48 / 219 44 / 92 e. lysine at position 119 of CLλ and aspartic acid at position 128 of CH1; f. lysine at position 119 of CLA and glutamic acid at position 128 of CH1; g. lysine at position 119 of CLA and serine at position 128 of CH1; and h. lysine at position 119 of CLA and threonine at position 128 of CH1.
[0125] In some respects, the lambda charge pair is located in the charge pair situated at position 134 in CLA and at position 128 in CH1. For example, the lambda charge pair can be selected from the following list: a. arginine at position 134 of CLA and aspartic acid at position 128 of CH1; b. arginine at position 134 of CLA and glutamic acid at position 128 of CH1; c. arginine at position 134 of CLA and serine at position 128 of CH1; d. arginine at position 134 of CLA and threonine at position 128 of CH1; e. lysine at position 134 of CLA and aspartic acid at position 128 of CH1; f. lysine at position 134 of CLA and glutamic acid at position 128 of CH1; g. lysine at position 134 of CLA and serine at position 128 of CH1; and h. lysine at position 134 of CLA and threonine at position 128 of CH1.
[0126] In some cases, the lambda charge pair is located in the charge pair situated at position 134 in CLA and at position 145 in CH1. For example, the lambda charge pair can be selected from the following list: a. arginine at position 134 of CLA and aspartic acid at position 145 of CH1; b. arginine at position 134 of CLA and glutamic acid at position 145 of CH1; c. arginine at position 134 of CLA and serine at position 145 of CH1; d. arginine at position 134 of CLA and threonine at position 145 of CH1; e. lysine at position 134 of CLA and aspartic acid at position 145 of CH1; f. lysine at position 134 of CLA and glutamic acid at position 145 of CH1; g. lysine at position 134 of CLA and serine at position 145 of CH1; and Petition 870260111560, dated 10 / 29 / 2026, page 49 / 219 45 / 92 h. lysine at position 134 of CLλ and threonine at position 145 of CH1.
[0127] In some cases, the lambda charge pair is located in the charge pair situated at position 134 in CLλ and at position 183 in CH1. For example, the lambda charge pair can be selected from the following list: a. arginine at position 134 of CLλ and aspartic acid at position 183 of CH1; b. arginine at position 134 of CLλ and glutamic acid at position 183 of CH1; c. arginine at position 134 of CLλ and serine at position 183 of CH1; d. arginine at position 134 of CLλ and threonine at position 183 of CH1; e. lysine at position 134 of CLλ and aspartic acid at position 183 of CH1; f. lysine at position 134 of CLλ and glutamic acid at position 183 of CH1; g. lysine at position 134 of CLλ and serine at position 183 of CH1; and h. lysine at position 134 of CLλ and threonine at position 183 of CH1.
[0128] In some cases, the lambda charge pair is a lysine at position 134 of CLλ and an aspartic acid or a serine at position 183 of CH1.
[0129] In some cases, the lambda charge pair is located in the charge pair situated at position 136 in CLλ and at position 185 in CH1. For example, the lambda charge pair can be selected from the following list: a. arginine at position 136 of CLλ and aspartic acid at position 185 of CH1; b. arginine at position 136 of CLλ and glutamic acid at position 185 of CH1; c. arginine at position 136 of CLλ and serine at position 185 of CH1; d. arginine at position 136 of CLλ and threonine at position 185 of CH1; e. lysine at position 136 of CLλ and aspartic acid at position 185 of CH1; f. lysine at position 136 of the CLÃ and glutamic acid at position 185 of the CH1; g. lysine at position 136 of CH1 and serine at position 185 of CH1; and h. lysine at position 136 of C1A and threonine at position 185 of CH1. Petition 870260111560, dated 10 / 29 / 2026, page 50 / 219 46 / 92
[0130] In some cases, the lambda charge pair is located in the charge pair situated at position 178 in CLλ and at position 173 in CH1. For example, the lambda charge pair can be selected from the following list: a. arginine at position 178 of CLλ and aspartic acid at position 173 of CH1; b. arginine at position 178 of CLλ and glutamic acid at position 173 of CH1; c. arginine at position 178 of CLλ and serine at position 173 of CH1; d. arginine at position 178 of CLλ and threonine at position 173 of CH1; e. lysine at position 178 of CLλ and aspartic acid at position 173 of CH1; f. lysine at position 178 of CLλ and glutamic acid at position 173 of CH1; g. lysine at position 178 of CLλ and serine at position 173 of CH1; and h. lysine at position 178 of CLλ and threonine at position 173 of CH1.
[0131] In some cases, the antigen-binding arm comprising a lambda-charge pair comprises more than one lambda-charge pair. For example, the antigen-binding arm may comprise two, three, four, five, six, seven, eight, or nine lambda-charge pairs at positions (i) to (ix) described above.
[0132] In some cases, an antigen-binding arm in the antibody comprises a pair of kappa charges. Pairs of kappa charges can be introduced at various positions to enhance the pairing of the correct light and heavy chains in the antigen-binding arm. As described above, kappa charge pairs refer to a positively charged amino acid residue and a negatively charged amino acid residue, one of which is located on the kappa light chain (e.g., CLk) and the other on the heavy chain (e.g., CH1) of an antigen-binding arm, situated at positions intended to promote the association of the light chain and CH1 of the antigen-binding arm.
[0133] In some cases, the antigen-binding arm comprises a pair of kappa charges located at position 133 on CLk and at position 183 on CH1. In some Petition 870260111560, dated 10 / 29 / 2026, p. 51 / 219 In 47 / 92 cases, the negatively charged amino acid residue in the kappa charge pair is at position 133 of CLk, and the positively charged amino acid residue in the kappa charge pair is at position 183 of CH1. In other cases, the positively charged amino acid residue in the kappa charge pair is at position 133 of CLk, and the negatively charged amino acid residue in the kappa charge pair is at position 183 of CH1. In some cases, the negatively charged amino acid residue (e.g., at position 133 of CLk) is glutamic acid, and the positively charged amino acid residue (e.g., at position 183 of CH1) is lysine. As mentioned elsewhere, this numbering is in accordance with EU numbering.
[0134] In some cases, one of the antigen-binding arms in the antibody comprises a pair of lambda charges and another (different) antigen-binding arm in the antibody comprises a pair of kappa charges. As exemplified here, the CD3 antigen-binding arm may comprise a pair of lambda charges and the target antigen-binding arm (e.g., the TAA antigen-binding arm) comprises a pair of kappa charges. Alternatively, the target antigen-binding arm (e.g., the TAA antigen-binding arm) may comprise a pair of lambda charges and the CD3 antigen-binding arm may comprise a pair of kappa charges.
[0135] The reference here to the pair or domain of loads in the singular (e.g., a or the) also covers multiple pairs of loads or multiple domains, unless the context clearly indicates otherwise.
[0136] The charge pairs described here can be combined with other strategies to promote heterodimerization, in order to further increase the correct pairing of heavy and light chain polypeptides.
[0137] Non-limiting examples of strategies to promote heterodimerization are described in more detail below and include the use of disulfide manipulation at the CH1 / CL interface, the introduction of charge pairs Petition 870260111560, dated 10 / 29 / 2026, page 52 / 219 Additional 48 / 92 (e.g., kappa charge pairs) and modifications of the Fc region, such as knobs-into-holes, enable fractional purification strategies. Fc region modifications
[0138] In some cases, the antibodies described herein comprise one or more modifications in one or more of the CH1, CH2, and CH3 domains that promote the formation of a heterodimeric antibody molecule, facilitating the formation of the Fc regions present in the antibody. This may involve a Knobs into Holes (KiH) strategy based on single amino acid substitutions in the CH3 domains that promote heavy chain heterodimerization, as described in Ridgway, 1996. The heavy chain variant knob CH3 has a small amino acid that has been replaced by a larger one, thus generating a protrusion (knob) on the surface of said CH3 domain, and the variant hole has a large amino acid replaced by a smaller one, thus generating a cavity (hole) on the surface of said CH3 domain. Additional modifications may also be introduced to stabilize the association between the heavy chains.
[0139] CH3 modifications to enhance heterodimerization include, for example, Y407V / T366S / L368A hole mutations in one Fc region and T366W knob mutation in the other Fc region. These may additionally include stabilizing Y349C cystine mutations (e.g., in the Fc region with the hole mutation) and stabilizing S354C mutations in the other Fc region (e.g., in the Fc region with the knob mutation).
[0140] Consequently, in one case, the substitution to generate a knob is a tryptophan substitution at position 366 and the substitution to generate a hole is one or more of the following: i) a substitution with valine at position 407; ii) a substitution with serine at position 366; and iii) a substitution with alanine at position 368.
[0141] For example, the single Fc region may include a modification to enable fractional elution by protein A chromatography, as described Petition 870260111560, dated 10 / 29 / 2026, p. 53 / 219 49 / 92 in Tustian, 2016. In summary, one of the Fc regions may comprise a modification that removes the binding to protein A (called Fc*), enabling the selective purification of the heterodimeric FcFc* bispecific product. Examples of suitable modifications to generate an Fc* region include the substitution of H435 with arginine and Y436 with phenylalanine.
[0142] Other Fc modifications that can be used besides those used to enhance heterodimerization are those that reduce or abolish the binding of the antibody molecule to one or more Fcy receptors, such as FcyRI, FcyRIIa, FcyRIIb, FcyRIII and / or complement. These mutations reduce or abolish the effector functions of Fc. Mutations that reduce or abolish the binding of an antibody molecule to one or more Fcy receptors and / or complement are known and include the triple mutation or TM of L234F / L235E / P331S (according to the European Union numbering convention) described, for example, in Organesyan et al., Acta Crystallogr D Biol Crystallogr 64(6): 700 to 704, 2008.
[0143] In some respects, the CH2 domain of one or both of the immunoglobulin heavy chain constant domains comprises the following substitutions: E233P / L234V / L235A / G236del / S267K. This combination of mutations may be referred to here as the Fc effector null mutation.
[0144] Other suitable Fc region amino acid substitutions or modifications are known in the art and include, for example, the triple substitution of methionine (M) for tyrosine (Y) at position 252, a substitution of serine (S) for threonine (T) at position 254, and a substitution of threonine (T) for glutamic acid (E) at position 256, numbered according to the EU index, as in Kabat (M252Y / S254T / T256E; referred to as YTE or YTE mutation) (see, for example, US Patent 7,658,921; US Patent Publication 2014 / 0302058; and Yu et al., Antimicrob. Agents Chemother., 61(1): e01020-16 (2017), each of which is incorporated herein by reference in its entirety). This combination of mutations can prolong the antibody's half-life. Petition 870260111560, dated 10 / 29 / 2026, page 54 / 219 50 / 92
[0145] The triple mutation, the Fc effector null mutation, and the YTE mutation, when present, may be present in one or both heavy chain constant domains. Typically, if included, they are included in both heavy chain constant domains.
[0146] In some respects, the Fc region comprises the YTE mutation and the triple mutation. In other respects, the Fc region comprises the YTE mutation and the Fc effector null mutation. Manipulated disulfides
[0147] In some cases, antibodies contain engineered disulfides. By engineered disulfides it is understood that a native interchain disulfide bond at the CH1-CL interface (e.g., at 220 of CH1 and 212 of LC) of the antigen-binding arm and, optionally, one or more additional antigen-binding arms, has been replaced by an engineered (non-native) interchain disulfide. An engineered disulfide is typically formed by manipulating cysteines in the CL of a light chain and in the CH1 of the corresponding heavy chain and replacing the cysteines that normally form the interchain disulfide. Disclosure relating to the introduction of engineered disulfide into antibodies for the purpose of promoting heterodimerization can be found, for example, in U.S. Patent No. 9,527,927, which is incorporated herein by reference in its entirety.
[0148] In some cases, the disulfide bond between the light chain and the CH1 in at least one of the antigen-binding arms is formed between a pair of cysteines manipulated in the light chain and the CH1 of that antigen-binding arm.
[0149] In some cases: (i) the disulfide bond between the light chain and the CH1 in the CD3 antigen-binding arm is formed between a pair of manipulated cysteines in the light chain and the CH1 of the CD3 antigen-binding arm, and the disulfide bond between the light chain and the CH1 in the target antigen-binding arm is formed between a pair of native cysteines. A schematic of this example is provided in Figure 20; or Petition 870260111560, dated 10 / 29 / 2026, page 55 / 219 51 / 92 (ii) the disulfide bond between the light chain and the CH1 in the target antigen-binding arm is formed between a pair of manipulated cysteines in the light chain and the CH1 of the target antigen-binding arm, and the disulfide bond between the light chain and the CH1 in the CD3 antigen-binding arm is formed between a pair of native cysteines.
[0150] In some cases, when the antibody is in a '2+1' format as described here: (i) the disulfide bond between the light chain and the CH1 in the CD3 antigen-binding arm is formed between a pair of manipulated cysteines in the light chain and the CH1 in the CD3 antigen-binding arm, and the disulfide bonds between the light chains and the CH1 in the two target antigen-binding arms are formed between pairs of native cysteines. A schematic of this example is provided in Figure 21; (ii) disulfide bonds between the light chains and the CH1 in the two target antigen-binding arms are formed between pairs of manipulated cysteines in the light chains and the CH1 in the two target antigen-binding arms, and the disulfide bond between the light chain and the CH1 in the CD3 antigen-binding arm is formed between a pair of native cysteines; or (iii) all three antigen-binding arms contain manipulated disulfides, but the manipulated cysteines in the CD3 antigen-binding arm are in different positions (e.g., on the light chain) from the manipulated cysteines in the target antigen-binding arms.
[0151] In some cases, when the antibody is in a trispecific format described herein, the disulfide bond between the light chain and the CH1 of the first antigen-binding arm (e.g., the CD3 antigen-binding arm) is formed between a pair of manipulated cysteines in the light chain and the CH1 of the first antigen-binding arm, the disulfide bond formed between the light chain and the CH1 of the second antigen-binding arm (e.g., the target antigen-binding arm) is formed between a pair of native cysteines of the second antigen-binding arm, and the disulfide bond formed between the light chain and the CH1 of the third arm. Petition 870260111560, dated 10 / 29 / 2026, page 56 / 219 A 52 / 92 antigen-binding arm (e.g., a CD8 target antigen-binding arm or a target antigen-binding domain that binds to a different target than the second antigen-binding arm) is formed between a pair of manipulated cysteines in the light chain and the CH1 of the first antigen-binding arm. A schematic of this example is provided in Figure 22.
[0152] In cases where the first and third antigen-binding arms contain manipulated disulfides, it is desirable that the manipulated disulfide introduced into the third antigen-binding arm be different from the manipulated disulfide introduced into the first antigen-binding arm, as this is believed to further improve correct pairing. Thus, optionally, the cysteine pair inserted into the third antigen-binding arm is in different amino acid residue positions than the cysteine pair inserted into the first antigen-binding arm.
[0153] As described above, light chains can comprise a CLλ or CLk. In some cases, the pair of cysteines involved in CLλ and CH1 is located at position 122 of CLλ and at position 126 of CH1, with CLλ comprising a non-cysteine residue at position 212 and CH1 comprising a non-cysteine residue at position 220. In some cases, the non-cysteine residues are valines.
[0154] An amino acid sequence exemplifying a CL1 comprising a manipulated cysteine is provided as SEQ ID NO: 107 and an amino acid sequence exemplifying the CH1 comprising the corresponding manipulated cysteine to form the manipulated disulfide is provided as SEQ ID NO: 108.
[0155] In some cases, the pair of cysteines manipulated in a constant kappa region of light chain (CLk) and CH1 are located at position 121 of CLk and at position 126 of CH1, and the same CLk comprises a non-cysteine residue at position 214 and the same CH1 comprises a non-cysteine residue at position 220. In some cases, the non-cysteine residues are valines. Petition 870260111560, dated 10 / 29 / 2026, page 57 / 219 53 / 92
[0156] In some cases, the antibody is in a 'DuetMab' format, for example, as described in US patent No. 9,527,927. A DuetMab includes manipulated disulfides to enhance correct heavy / light chain pairing and Fc region modifications to enhance correct heterodimerization of heavy chains.
[0157] In some respects, the antibody comprises: a CD3 antigen-binding arm, as described above, comprising a first Fc region; and a target antigen-binding arm, as described above, comprising a second Fc region, wherein the first and second Fc regions comprise modifications to facilitate heterodimerization of the first and second Fc regions.
[0158] In some respects, the antibody comprises: an antigen-binding arm for CD3, as described above, comprising a first Fc region; and an antigen-binding arm for target, as described above, comprising a second Fc region, wherein the first and second Fc regions comprise modifications to facilitate heterodimerization of the first and second Fc regions, and wherein the antibody comprises manipulated disulfides.
[0159] In some respects, the antibody comprises: a CD3 antigen-binding arm comprising a pair of lambda charges, as described above, and a first Fc region; and a target antigen-binding arm, as described above, comprising a second Fc region, wherein the first and second Fc regions comprise modifications to facilitate heterodimerization of the first and second Fc regions.
[0160] In some respects, the antibody comprises: Petition 870260111560, dated 10 / 29 / 2026, page 58 / 219 54 / 92 a CD3 antigen-binding arm comprising a pair of lambda charges, as described above, and a first Fc region; and a target antigen-binding arm, as described above, comprising a second Fc region, wherein the first and second Fc regions comprise modifications to facilitate heterodimerization of the first and second Fc regions, and wherein the antibody comprises manipulated disulfides.
[0161] In some respects, the antibody comprises: a CD3 antigen-binding arm comprising a pair of lambda charges, as described above, and a first Fc region; and a target antigen-binding arm comprising a pair of kappa charges, as described above, and a second Fc region, wherein the first and second Fc regions comprise modifications to facilitate heterodimerization of the first and second Fc regions.
[0162] In some respects, the multispecific antibody comprises: a CD3 antigen-binding arm comprising a lambda charge pair, as described above, and a first Fc region; and a target antigen-binding arm comprising a kappa charge pair, as described above, and a second Fc region, wherein the first and second Fc regions comprise modifications to facilitate heterodimerization of the first and second Fc regions, and wherein the multispecific antibody comprises manipulated disulfides.
[0163] Non-limiting examples of antibodies comprising a lambda charge pair, a kappa charge pair, manipulated disulfides, and modifications to facilitate heterodimerization of the first and second Fc regions are provided in the examples. Sequence identity and mutations
[0164] In some cases, the CLA described here comprises an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Petition 870260111560, dated 10 / 29 / 2026, page 59 / 219 55 / 92% or 99% identity with SEQ ID NO: 105 or SEQ ID NO: 107. In some cases, CLλ comprises an amino acid sequence from SEQ ID NO: 105 or SEQ ID NO: 107 with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid modifications.
[0165] In some cases, the CLk described herein comprises an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 106. In some cases, the CLk comprises an amino acid sequence of SEQ ID NO: 106 with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.
[0166] In some cases, the CH1 described herein comprises an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 101 or SEQ ID NO: 108. In some cases, CH1 comprises an amino acid sequence of SEQ ID NO: 101 or SEQ ID NO: 108 with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.
[0167] In some cases, the CH2 described herein comprises an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 102. In some cases, the CH2 comprises an amino acid sequence of SEQ ID NO: 102 with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.
[0168] In some cases, the CH3 described herein comprises an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 103. In some cases, the CH3 comprises an amino acid sequence of SEQ ID NO: 103 with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.
[0169] Modifications of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in the constant regions (CLλ, CLk, CH1, CH2, and CH3) may be additional to the modifications described above to introduce the charge pairs, manipulated disulfides, and / or Fc region modifications described above. For example, compared to the Petition 870260111560, dated 10 / 29 / 2026, page 60 / 219 56 / 92 The wild-type CLA presented in SEQ ID NO: 105, the CLA used in the antibody may contain a lambda charge pair mutation, a manipulated disulfide (e.g., S122C and C212V), and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid modifications. As another example, compared to the wild-type CH1 provided in SEQ ID NO: 101, a CH1 used in the antibody may contain a lambda charge mutation, a manipulated disulfide (e.g., F126C, C220V), and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid modifications.
[0170] In some cases, the CD3 antigen-binding domain comprises a VH region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the amino acid sequences defined in (16) to (24) above. In some cases, the CD3 antigen-binding domain comprises a VH region with the amino acid sequences defined in (16) to (24) above with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.
[0171] In some cases, the CD3 antigen-binding domain comprises a VL region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the amino acid sequences defined in (25) to (27) above. In some cases, the CD3 antigen-binding domain comprises a VL region with the amino acid sequences defined in (25) to (27) above with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.
[0172] The CLA regions described herein comprise an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 105 or SEQ ID NO: 107. In some cases, the CLA comprises an amino acid sequence from SEQ ID NO: 105 or SEQ ID NO: 107 with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid modifications.
[0173] In some cases, the CD3 antigen-binding domain comprises a VH region according to any one of (16) to (24) below:
[0174] An amino acid modification can be an insertion, a substitution, or a deletion. In some respects, amino acid modification is Petition 870260111560, dated 10 / 29 / 2026, p. 61 / 219 57 / 92 a substitution of an amino acid residue for any other naturally occurring or unnatural amino acid residue.
[0175] Naturally occurring residues can be divided into classes based on common side-chain properties: 1) Nonpolar, aliphatic: glycine (G), methionine (M), alanine (A), valine (V), leucine (L), isoleucine (I); 2) polar: cysteine (C), asparagine (N), glutamine (Q), proline (P); 3) Polar, partially negatively charged: serine (S), threonine (T); 4) Acid (negatively charged): aspartic acid (D), glutamic acid (E); 5) Basic (positively charged): histidine (H), lysine (K), arginine I; 6) aromatic: tryptophan (W), tyrosine (Y), phenylalanine (F).
[0176] As described above, serine (S) and threonine (T) have an isoelectric point below 6 and are partially negatively charged at neutral pH, therefore they are classified here as 'polar, partially negatively charged'.
[0177] Amino acid substitution can be a conservative amino acid substitution. Conservative amino acid substitutions can involve exchanging one member of one of these classes for another member of the same class. For example, a conservative amino acid substitution could be a substitution of the amino acid glutamic acid (E) for the amino acid aspartic acid (D). Nucleic acids, vectors and host cells
[0178] One or more nucleic acids encoding the antibody described herein are also provided herein. In some cases, the nucleic acid(s) is / are purified or isolated, for example, from another nucleic acid or naturally occurring biological material. One skilled in the art would have no difficulty in preparing these nucleic acid molecules using methods well known in the art.
[0179] In some cases, one or more nucleic acids encode a light chain as described herein and / or a CH1 as described herein. One or more Petition 870260111560, dated 10 / 29 / 2026, page 62 / 219 58 / 92 nucleic acids that encode CH1 can additionally encode other heavy chain domains, for example, the hinge, CH2 and CH3, and can encode a complete heavy chain.
[0180] The present disclosure also provides one or more vectors comprising nucleic acid(s) encoding an antibody or fragment thereof described herein. Suitable vectors may be chosen or constructed, containing suitable regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences, as appropriate. Preferably, the vector contains regulatory sequences suitable for driving nucleic acid expression in a host cell. Vectors may be plasmids, for example, viral phage or phagemid, as appropriate.
[0181] The antibody can be produced from a light chain vector and a heavy chain vector. A light chain vector can contain the nucleic acid encoding one of the light chains in the antibody and the nucleic acid encoding the other light chain, which can be present in the vector as separate cassettes (e.g., each operationally connected to a different promoter). Similarly, a heavy chain vector can be used to encode both the CH1 (and the Fc region, if present) of one antigen-binding arm and the CH1 (and the Fc region, if present) of the other antigen-binding arm, which can be present in the vector as separate cassettes. Alternatively, separate vectors can be used to encode each of the light chains, CH1s, and Fc regions (if present).
[0182] A nucleic acid molecule or a vector, as described herein, may be introduced into a host cell. Techniques for introducing nucleic acid or vectors into host cells are well established in the art and any suitable technique may be employed. A range of host cells suitable for the production of recombinant antibody molecules is known in the art and includes bacterial, yeast, and insect host cells. Petition 870260111560, dated 10 / 29 / 2026, page 63 / 219 59 / 92 or mammalian. In some respects, the host cell is a mammalian cell, such as a CHO, NS0, or HEK cell, for example, a HEK293 cell. In some respects, the host cell is a CHO cell. Antibody production methods
[0183] A method for producing the antibody described herein is also provided herein. Techniques for purifying recombinant antibody molecules are well known in the art and include, for example, high-performance liquid chromatography, fast liquid protein chromatography, ion-exchange chromatography, and affinity chromatography, for example, using Protein A or Protein L or by binding to an affinity tag. In some cases, purification is performed using affinity chromatography (e.g., Protein A affinity chromatography). In some cases, purification additionally comprises (e.g., in addition to Protein A chromatography) light chain affinity chromatography.
[0184] The method may also comprise formulating the antibody molecule into a pharmaceutical composition, optionally with a pharmaceutically acceptable excipient or other substance as described below. Treatment
[0185] The antibodies described here may be useful for therapeutic applications, such as in cancer treatment.
[0186] An antibody, as described herein, may be used in a method of treating the human or animal body. Related aspects of the disclosure provide; (i) an antibody described herein for use as a medicament, (ii) an antibody described herein for use in a method of treating a disease or disorder, (iii) an antibody described herein in the manufacture of a medicament for use in treating a disease or disorder; and Petition 870260111560, dated 10 / 29 / 2026, page 64 / 219 60 / 92 (iv) a method of treating a disease or disorder in an individual, wherein the method comprises administering to the individual a therapeutically effective amount of an antibody described herein.
[0187] The individual can be a patient, preferably a human patient.
[0188] Treatment may be any treatment or therapy in which some desired therapeutic effect is achieved, for example, inhibition or delay of the condition process and includes a reduction in the rate of progression, a halt in the rate of progression, improvement of the condition, cure or remission (partial or total) of the condition, preventing, improving, delaying, attenuating or interrupting one or more symptoms and / or signs of the condition or prolonging the survival of an individual or patient beyond what would be expected in the absence of treatment.
[0189] Treatment as a prophylactic measure (i.e., prophylaxis) is also included. For example, an individual susceptible to or at risk of developing or developing a disease such as cancer may be treated as described herein. This treatment may prevent or delay the occurrence or recurrence of the disease in the individual.
[0190] Although an antibody can be administered alone, antibodies or fragments thereof will generally be administered in the form of a pharmaceutical composition, which may comprise at least one component in addition to the antibody. Another aspect of the disclosure therefore provides a pharmaceutical composition comprising an antibody as described herein. A method comprising formulating an antibody into a pharmaceutical composition is also provided.
[0191] Pharmaceutical compositions may comprise, in addition to the antibody, an excipient, a vehicle, a buffer, a pharmaceutically acceptable stabilizer, or other materials well known to those skilled in the art. The term pharmaceutically acceptable, as used herein, refers to compounds, materials, compositions, and / or dosage forms that are, within the scope of medical judgment, suitable for use in contact with the tissues of a Petition 870260111560, dated 10 / 29 / 2026, page 65 / 219 61 / 92 individual (e.g., human being) without excessive toxicity, irritation, allergic response, or other problem or complication, proportionate to a reasonable risk / benefit ratio.
[0192] The administration may be in a therapeutically effective amount, sufficient to show benefit to an individual. The actual amount administered and the rate and timing of administration will depend on the nature and severity of what is being treated, the specific individual being treated, the individual's clinical condition, the cause of the disorder, the site of application of the composition, the type of antibody molecule, the method of administration, and the administration schedule.
[0193] ***
[0194] The features disclosed in the foregoing description or in the following claims or in the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for achieving the disclosed results, as appropriate, may, separately or in any combination of such features, be used to realize the disclosure in various forms thereof.
[0195] Although the disclosure has been described in conjunction with the exemplary cases described above, many equivalent modifications and variations will be apparent to those skilled in the art when given this disclosure. Consequently, the exemplary cases of the disclosure presented above are considered illustrative and not limiting. Various alterations to the described cases may be made without departing from the spirit and scope of the disclosure.
[0196] For the avoidance of doubt, any theoretical explanations provided herein are given for the purpose of improving a reader's understanding. Any section headings used in the present invention are for organizational purposes only and should not be construed as limiting the subject matter described. Petition 870260111560, dated 10 / 29 / 2026, page 66 / 219 62 / 92
[0197] Throughout this descriptive report, including the claims that follow, unless the context requires otherwise, the word comprehend and include and variations such as comprehends, which comprehends and including will be understood as implying the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps.
[0198] It should be noted that, as used in the descriptive report and appended claims, the singular forms a, an, or include plural references, unless the context clearly indicates otherwise. Ranges may be expressed in the present invention from about a specific value and / or to about another specific value. When such a range is expressed, another aspect includes from the specific value and / or to the other specific value. Similarly, when values are expressed as approximations, by using the antecedent about, it will be understood that the specific value forms another aspect. The term about in relation to a numerical value is optional and means, for example, + / - 10%. Table 1 - Sequences _______________________________________________ SEQ ID NO: Descrição Sequência 1 Vk parental DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQ KPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQYPFTFGSGTKVEIK 2 LCDR1 and Vk parental KSSQSLVHNNANTYLS 3 HCDR1 6 HCDR1 de VH KAWMH 7 HCDR2 de VH QIKDKSNSYATYYADSVKG 8 HCDR3 de VH RGVYYALSPFDY 9 Vk 3 DIVMTQSPLSLPVTPGEPASISCRSSQSLVHNQANTYLSWYLQ KPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQYPFTFGSGTKVEI K Petition 870260111560, on 10 / 29 / 2026, page. 67 / 219 63 / 92 10 LCDR1 in Vk 3 rssqslvhnqantyls 11 LCDR2 in Vk 3 kvsnrfs 12 LCDR3 in Vk 3 GQGTQYPFT 13 Vk 7 divmtqsplslpvtpgepasiscrssqslvhntgntylswylq 14 LCDR1 Vk 7 rssqslvhntgntyls 15 LCDR2 Vk 7 kvsnras 16 LCDR3 Vk 7 GQGTQYPFT 17 Vk 11 divmtqsplslpvtpgepasiscrssqslvhnqantylswylq kpgqspqsliykvsnrysgvpdrfsgsgsgtdftlkisrveae dvgvyycgqgtqypftfgsgtkvei k 18 LCDR1 de Vk 11 rssqslvhnqantyls 19 LCDR2 de Vk 11 kvsnrys 20 LCDR3 de Vk 11 GQGTQYPFT 21 VH 1 evqlvesggalvkpggslrlscaasgftftkawmhwvrqap gkqlewvaqikdksnsyatyyaesvkgrftisrddskntlylq mnslktedtavyycrgvyyalspfdywgqgtlvtvss 22 HCDR1 de VH 1 KAWMH 23 HCDR2 de VH2 qikdksnsyatyyaesvkgr 24 HCDR3 de VH3 rgvyyalspfdy 25 VH 7 evqlvesggalvkpggslrlscaasgftftkaymhwvrqap gkqlewvaqikdksnsyatyyaesvkgrftisrddskntlylq mnslktedtavyycrgvyyalspfdywgqgtlvtvss 26 HCDR1 de VH 7 KAYMH 27 HCDR2 de VH7 qikdksnsyatyyaesvkgr 28 HCDR3 de VH7 rgvyyalspfdy 29 VH 8evqlvesggalvkpggslrlscaasgftfsnawmhwvrqap gkqlewvaqikdksnsyatyyaesvkgrftisrddskntlylq mnslktedtavyycrgvyyalspfdywgqgtlvtvss 30 HCDR1 de VH 8 NAWMH 31 HCDR2 de VH 8 qikdksnsyatyyaesvkgr 32 HCDR3 de VH 8 rgvyyalspfdy 33 VH 9 evqlvesggalvkpggslrlscaasgftftkawmswvrqap gkqlewvaqikdksnsyatyyaesvkgrftisrddskntlylq mnslktedtavyycrgvyyalspfdywgqgtlvtvss 34 HCDR1 de VH 9 KAWMS 35 HCDR2 de VH9 qikdksnsyatyyaesvkgr 36 HCDR3 de VH9 rgvyyalspfdy 37 VH 13 evqlvesggalvkpggslrlscaasgftftkaymhwvrqap gkqlewvaqikdrsqsyatyyaesvkgrftisrddskntlylq mnslktedtavyycrgvyyalspfdywgqgtlvtvss 38 HCDR1 de VH 13 KAYMH 39 HCDR2 de VH 13 qikdrsqsyatyyaesvkgr 40 HCDR3 de VH 13 rgvyyalspfdy Petition 870260111560, on 10 / 29 / 2026, page. 68 / 219 64 / 92 21 VH QIKDRSQSYATYYAESVKGR 44 HCDR3 de VH 21 RGVYYALSPFDY 45 Vk 17 DIVMTQSPLSLPVTPGEPASISCRSSQSLVHNTGNTYLSWYLQ KPGQSPQSLIYKVSNRASGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQAPFTFGSGTKVEIK 46 LCDR1 de Vk 17 RSSQSLVHNTGNTYLS 47 LCDR2 de Vk 17 KVSNRAS 48 LCDR3 de Vk 17 GQGTQAPFT 49 VH 35 evqlvesggalvkpggslrlscaasgftfsnawmhwvrqap GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYALAPFDYWGQGTLVTVSS 50 HCDR1 de VH 35 NAWMH 51 HCDR2 de VH 35 QIKDRSQTYATYYAESVKGR 52 HCDR3 de VH 35 RGVYYALAPFDY 53 VH 37 evqlvesggalvkpggslrlscaasgftftkaymhwvrqap GKQLEWVAQIKDRSQSYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYALAPFDYWGQGTLVTVSS 54 HCDR1 de VH 37 KAYMH 55 HCDR2 de VH 37 QIKDRSQS 56 HCDR3 de VH 37 RGVYYALAPFDY 57 Vk 26 DIVMTQSPLSLPVTPGEPASISCRSSQSLVHNTGNTYLSWYLQ kpgqspqsliykvsnrasgvpdrfsgsgsgtdftlkisrveaeDVGVYYCGQGTQAPFSFGSGTKVEIK 58 LCDR1 in Vk 26 RSSQSLVHNTGNTYLS 59 LCDR2 in Vk 26 KVSNRAS 60 LCDR3 in Vk 26 GQGTQAPFS 61 Vk 29 DIVMTQSPLSLPVTPGEPASISCRSSQSLVHNTGNTYLSWYLQ KPGQSPQSLIYKVSNRASGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQFPFTFGSGTKVEIK 62 LCDR1 of Vk 29 RSSQSLVHNTGNTYLS 63 LCDR2 of Vk 29 KVSNRAS 64 LCDR3 of Vk 29 GQGTQFPFT 65 VH R75 evqlvesggalvkpggslrlscaasgftftrawmhwvrqap GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYANAPFDYWGQGTLVTVSS 66 HCDR1 de VH R75 RAWMH 67 HCDR2 de VH R75 QIKDRSQTYATYYAESVKGR 68 HCDR3 de VH R75 RGVYYANAPFDY 69 VH R79 evqlvesggalvkpggslrlscaasgftftrawmhwvrqap GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYAVTPFDYWGQGTLVTVSS Petition 870260111560, on 10 / 29 / 2026, page. 69 / 219 65 / 92 70 HCDR1 de VH R79 RAWMH 71 HCDR2 de VH R79 QIKDRSQTYATYYAESVKGR 72 HCDR3 de VH R79 RGVYYAVTPFDY 73 VH R82 EVQLVESGGALVKPGGSLRLSCAASGFTFTRAWMHWVRQAP GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYANTPFDYWGQGTLVTVSS 74 HCDR1 de VH R82 RAWMH 75 HCDR2 de VH R82 QIKDRSQTYATYYAESVKGR 76 HCDR3 de VH R82 RGVYYANTPFDY 77 VH SN75 EVQLVESGGALVKPGGSLRLSCAASGFTFSNAWMHWVRQAP GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYANAPFDYWGQGTLVTVSS 78 HCDR1 de VH SN75 NAWMH 79 HCDR2 de VH SN75 QIKDRSQTYATYYAESVKGR 80 HCDR3 de VH SN75 RGVYYANAPFDY 81 VH SN79 EVQLVESGGALVKPGGSLRLSCAASGFTFSNAWMHWVRQAP GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYAVTPFDYWGQGTLVTVSS 82 HCDR1 de VH SN79 NAWMH 83 HCDR2 de VH SN79 QIKDRSQTYATYYAESVKGR 84 HCDR3 de VH SN79 RGVYYAVTPFDY 85 VH SN82 EVQLVESGGALVKPGGSLRLSCAASGFTFSNAWMHWVRQAP GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYANTPFDYWGQGTLVTVSS 86 HCDR1 de VH SN82 NAWMH 87 HCDR2 de VH SN82 QIKDRSQTYATYYAESVKGR88 HCDR3 de VH SN82 RGVYYANTPFDY 89 VH E75 EVQLVESGGALVKPGGSLRLSCAASGFTFTEAWMHWVRQAP GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYANAPFDYWGQGTLVTVSS 90 HCDR1 de VH E75 EAWMH 91 HCDR2 de VH E75 QIKDRSQTYATYYAESVKGR 92 HCDR3 de VH E75 RGVYYANAPFDY Petition 870260111560, on 10 / 29 / 2026, page. 70 / 219 66 / 92 93 VH E79 EVQLVESGGALVKPGGSLRLSCAASGFTFTEAWMHWVRQAP GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYAVTPFDYWGQGTLVTVSS 94 HCDR1 de VH E79 EAWMH 95 HCDR2 de VH E79 QIKDRSQTYATYYAESVKGR 96 HCDR3 de VH E79 RGVYYAVTPFDY 97 VH E82 EVQLVESGGALVKPGGSLRLSCAASGFTFTEAWMHWVRQAP GKQLEWVAQIKDRSQTYATYYAESVKGRFTISRDDSKNTLYLQ MNSLKTEDTAVYYCRGVYYANTPFDYWGQGTLVTVSS 98 HCDR1 de VH E82 EAWMH 99 HCDR2 of VH E82 QIKDRSQTYATYYAESVKGR 100 HCDR3 of VH E82 RGVYYANTPFDY 101 IgG1 CH1 ASTKGPSVFPLAPSSKSTSGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV 103 IgG1 CH3 NHKPSNTKVDKRVEPKSC 102 IgG1 CH2 GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 104 Continuous use of IgG1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 105 constant region lambda (CLλ) GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWK ADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSY SCQVTHEGSTVEKTVAPTECS 106 constant region kappa (CLk) RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC 107 Region CLλ V12' modified to form a manipulated disulfide bridge GQPKAAPSVTLFPPCSEELQANKATLVCLISDFYPGAVTVAWK ADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSY SCQVTHEGSTVEKTVAPTEVS 108 Region CH1 'V12' modified to form a manipulated disulfide bridge ASTKGPSVCPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKRVEPKSV 109 HCDR1 of CD8 VHH DDYAIG Petition 870260111560, dated 10 / 29 / 2026, page 71 / 219 67 / 92 110 HCDR2 of CD8 VHH CIRVSDGSTYYADSVKG 111 HCDR3 of CD8 VHH GSLYTCVQSIVWPARPYYDMDY 112 CD8VHH EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYAIGWFRQAPG KEREGVSCIRVSDGSTYYADSVKGRFTISRDNSKNTLYLQMNS LRAEDTAVYYCAAGSLYTCVQSIVWPARPYYDMDYWGQGTL VTVSS 113 Ligand GGGGS 114 Ligand SGGGGS 115 Ligand GGGGSGGGGS 116 HCDR1 of CD8 VHH TDYAIG 117 HCDR1 of CD8 VHH SDYAIG 118 CD8VHH EVQLLESGGGLVQPGGSLRLSCAASGFTFTDYAIGWFRQAPG KEREGVSCIRVSDGSTYYADSVKGRFTISRDSSKNTLYLQMNS LRAEDTAVYYCAAGSLYTCVQSIVWPARPYYDMDYWGQGTL VTVSS 119 CD8VHH EVQLLESGGGLVQPGGSLRLSCAASGFTFTDYAIGWFRQAPG KEREGVSCIRVSDGSTYYADSVKGRFTISRDNAKNTLYLQMNS LRAEDTAVYYCAAGSLYTCVQSIVWPARPYYDMDYWGQGTL VTVSS 120 CD8 VHH EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAIGWFRQAPG KEREGVSCIRVSDGSTYYADSVKGRFTISRDTSKNTLYLQMNS LRAEDTAVYYCAAGSLYTCVQSIVWPARPYYDMDYWGQGTL VTVSS Examples Example 1 - Materials and methods Cells and media
[0199] Cell lines that express CD3, including HPB-ALL, HSC-F, Jurkat, Jurkat TCR KO, and EGFR-expressing cell lines, including NCI H358 and MDA-MB468, were obtained from the American Type Culture Collection. All cell lines, except MDA-MB-468 cells, were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FBS and cultured in an incubator at 37°C with 80% humidity and 5% CO2. MDA-MB-468 cells were maintained in Leibovitz L-15 medium supplemented with 10% heat-inactivated FBS and cultured in an incubator at 37°C with 80% humidity. Petition 870260111560, dated 10 / 29 / 2026, page 72 / 219 68 / 92 Antibody expression constructs
[0200] Preliminary anti-CD3 variants were generated in bivalent monospecific IgG1™ format (L234F / L235E / P331S) for affinity and cross-reactivity assessments. DNA encoding Vk and VH of prospective anti-CD3 variants was obtained from Integrated DNA Technologies (IDT, Coralville, IA) and assembled into appropriately digested pOE-IgG1™ (kLC) using NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs, cat. no. E2621).
[0201] For the production of monovalent bispecific antibodies, the DuetMab platform was used (Mazor et al., 2015). DuetMab EGFR-CD3 expression constructs encoding the variable domains of anti-EGFR GA201 (Gerdes et al., 2013) and the variable domains of the generated CD3 sequences were created. Since both anti-EGFR and anti-CD3 were derived from parental antibodies containing κ, pDuetLight vectors were constructed encoding anti-EGFR GA201 VL with the constant κ domain and wild-type cysteine, and anti-CD3 VL with the constant λ domain with S121C. In addition, pDuetHeavy vectors were constructed encoding the VH anti-EGFR GA201 and VH anti-CD3 variants. These pDuetHeavy vectors encoded IgG1™ (L234F / L235E / P331S) to abolish Fc-mediated effector function. Only sequence-verified expression constructs were used in temporary transfections for antibody production. Antibody expression and purification
[0202] Preliminary anti-CD3 variants were produced from temporary transfection of HEK293F cells using 293Fectin™ (Life Technologies) in serum-free FreeStyle293™ medium according to the manufacturer's protocol. HEK293F cell culture supernatants containing antibodies were harvested 6 days post-transfection, filtered through a sterile 0.22 μm filter, and antibody concentrations were measured using protein A biosensors on an Octet384 instrument (ForteBio) according to the manufacturer's protocol. Antibodies were purified using MabSelect SuRe resin (GE Healthcare), eluted with Pierce IgG elution buffer, pH 2.0, and buffer exchanged in solution. Petition 870260111560, dated 10 / 29 / 2026, page 73 / 219 69 / 92 phosphate-buffered saline (PBS), pH 7.2 (Life Technologies). Antibody purity was assessed by HP-SEC and commonly yielded >95% monomer.
[0203] DuetMabs were produced by temporary cotransfection of cells CHO-K1 with pDuetHeavy and pDuetLight-based expression vectors using lipofectamine and proprietary media. CHOK1 cell culture supernatants were harvested 10 or 12 days post-transfection, filtered, and antibodies in the culture supernatants were quantified. DuetMabs were initially purified by MabSelect SuRe affinity chromatography and buffer exchanged at STF, pH 7.2. DuetMabs were then assessed for light chain mismatch by Bioanalyzer A (Agilent) analysis and, when necessary, further purified by LambdaFabSelect affinity chromatography (Cytiva) according to the manufacturer's protocol. After buffer exchange at STF, pH 7.2, DuetMabs were loaded onto a Superdex 200 16 / 600 column and monomer-containing fractions were collected. The DuetMabs were then evaluated for purity and light chain mismatch by HPSEC and Bioanalyzer A, respectively.All DuetMabs exhibited >98% monomer, >95% light chain correct pairing, and <0.5 mg / EU of endotoxin. HP-SEC
[0204] Antibodies were analyzed using HP-SEC to determine purity, including aggregate, monomer, and fragment levels. Samples (100 μg in STF) were injected into an Agilent 1200 series high-performance liquid chromatography (HPLC) instrument and separated using a TSKgel G3000SWxl size exclusion column (Tosoh Bioscience No. 08541). The mobile phase was 100 mM sodium phosphate (pH 6.8) and the sample flow rate was 1 mL / min. Proteins were detected using absorbance at 280 nm. Petition 870260111560, dated 10 / 29 / 2026, page 74 / 219 70 / 92 Flow cytometry measurement
[0205] Flow cytometry was used to determine specific binding to cell surface antigen. Human leukemia T cell lines HPBALL, Jurkat, Jurkat TCR KO and the cynomolgus monkey T cell line HSC-F were used to evaluate human CD3 and cynomolgus monkey CD3 binding, respectively. Briefly, 1 x 10⁵ cells were suspended in FACS buffer (1x STF, pH 7.2 supplemented with 2% heat-inactivated FBS, 0.1% sodium azide and 2 mM EDTA) and placed in each well of a 96-well round-bottom plate. Antibodies were diluted to various concentrations using FACS buffer and added to the cells. Antibodies and cells were washed twice with FACS buffer after incubation at 4 °C for 30 min. Antibody binding to cell surface antigen was detected with goat F(ab')2 fragment conjugated with Alexa Fluor 647 specifically against the human IgG Fcy fragment.Data were collected using a BD FACSymphony A3 cell analyzer (BD Biosciences). Data were analyzed with FlowJo v10.6.1 and plotted using GraphPad Prism v9.0.0. EGF receptor density analysis
[0206] Quantitative receptor density analysis in tumor cell lines was performed by flow cytometry on a BD FACSymphonyTMA3 Cell Analyzer (BD Biosciences). Briefly, human anti-EGFR IgG1 was first labeled with Alexa Fluor 647 using a protein labeling kit (Invitrogen) according to the manufacturer's instructions. Antibody concentration and fluorochrome-to-protein (F:P) ratio were determined by an ND1000 spectrophotometer (NanoDrop). Detached tumor cells were washed and resuspended with ice-cold FACS buffer (1x STF pH 7.2, 2% heat-inactivated FBS, 2 mM EDTA, and 0.1% sodium azide). Two x 10⁶ cells were then incubated with antibodies conjugated to Alexa Fluor 647 at saturated concentrations (> 20 μg / ml) for 1 ha at 4 °C. After washing with FACS buffer, the cells were fixed in ice-cold 1.8% paraformaldehyde (PFA) and the detection of bound antibodies was... Petition 870260111560, dated 10 / 29 / 2026, page 75 / 219 71 / 92 performed on the BD FACSymphony A3 Cell Analyzer using BD FACSDiva™ software. Results were analyzed using FlowJo analysis software (Tree Star). For quantification of EGFR receptor density in cells, Quantum Alexa Fluor 647 MESF (Equivalent Soluble Fluorochrome Molecules) microspheres (Bangs Laboratories) were analyzed in a flow cytometer using similar settings to establish a standard curve. Using QuickCal software (Bangs Laboratories), the calculated MESF was then divided by the F:P antibody ratio to yield a corrected Antibody Binding Capacity (ABC). Cytotoxicity and T cell activation
[0207] T-cell mediated cytotoxicity and T-cell activation were assessed by flow cytometry measurement. Cell-specific growth medium (RPMI 1640 + 10% FBS for NCI H358 or L-15 + 10% FBS for MDA-MB-468) supplemented with 50 μM β-mercaptoethanol was used as assay medium. A total of 1 x 10⁴ EGFR+ target cells (NCI H358 or MDA-MB-468) were stained with CellTrace Violet (ThermoFisher Scientific) and inoculated into each well of a 96-well round-bottom plate treated with tissue culture. Effector cells, CMSPs from a healthy donor, were added at an E:T ratio of 10:1 and antibodies were added at various concentrations. After one day of incubation at 37 °C in a humidified incubator (5% CO2 for NCI H358 or 0% CO2 for MDA-MB-468), all cells from the cytotoxicity assay were harvested, stained, and analyzed by flow cytometry using a Symphony A3 (BD).EGFR+ target cells were identified by CellTrace Violet staining, and T cells were identified by staining with CD4+ or CD8+. T cell activation was determined by CD69+ and CD25+. Data were analyzed using FlowJo v10.6.1. Cellular cytotoxicity was normalized to the minimum cytotoxicity value without antibody treatment and plotted using GraphPad Prism v9.0.0. Petition 870260111560, dated 10 / 29 / 2026, page 76 / 219 72 / 92 Cytokine release assay
[0208] Cytokines released into supernatants from cytotoxicity assays were evaluated using ProcartaPlex Human, NHP, and Canine Mix & Match Panels Luminex Kit (ThermoFisher Scientific) according to the manufacturer's protocol. Plates were read on the Bio-Plex 3D suspension array system (Bio-Rad) using Luminex xPONENT software. Data were analyzed and plotted using GraphPad Prism v9.0.0. Evaluation of T cell activation in the absence of EGFR+ cells.
[0209] To evaluate the level of T cell activation induced by anti-CD3 variants in the absence of EGFR+ cells, a plate-based CMSP incubation assay was used. 96-well flat-bottom plates were coated overnight at 4 °C with varying concentrations of T cell engager (50, 5.0, 0.5 nM) in 50 µl. The plates were then washed twice with STF, pH 7.2 before the addition of 150,000 CMSPs in 200 µl of AIM V medium. The CMSPs were incubated for 48 hours at 37 °C. The CMSPs were then transferred to a 96-well round-bottom plate, centrifuged, and the cell pellets were washed twice in STF and stained for CD69 and CD25 expression using an anti-CD2, -CD3, -CD4, -CD8, -CD25, -CD69 antibody panel by flow cytometry. Kinetic measurements
[0210] The binding kinetics of anti-CD3 variant-based DuetMabs were determined using Octet analysis. Biotinylated recombinant human CD3εδ (Acro Biosystems, CDD-H82W6) was immobilized on streptavidin sensors at a concentration of 1 pg / ml followed by 2-fold dilutions of anti-CD3 variant DuetMabs. For the parental anti-CD3 DuetMab, concentrations of 300 to 4.7 nM were evaluated. For anti-CD3 variant DuetMabs, concentrations of 5 pM to 78.1 nM or 8 pM to 125 nM were used. The kinetics were analyzed using a 1:1 antibody:antigen binding model. Petition 870260111560, dated 10 / 29 / 2026, p. 77 / 219 73 / 92 AC-SINS
[0211] Affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) was used to evaluate antibody self-association and was performed as described elsewhere (Dippel et al., 2023). Briefly, 5 μl of nanoparticles were mixed with 45 μl of purified antibody at 50 µg / ml in STF, pH 7.2 or HSA buffer [histidine 20 mM, sucrose 120 mM, arginine 80 mM, pH 6] in a 384-well plate. Nanoparticles were mixed with buffer only (without antibody) as a control. Absorbance was measured on a SPECTROstar Nano UV / vis plate reader from 490 to 700 nm. The peak absorbance wavelength was calculated using MARS data analysis software and used to determine the wavelength shift compared to the control containing only nanoparticles. Differential scanning fluorimetry
[0212] Differential-scanning fluorimetry (DSF) was used to evaluate the thermal melting temperatures of DuetMabs. Measurements were performed using a previously established method with minor modifications (Shan et al., 2018). Samples were prepared by combining 20 µl of 1 mg / ml protein sample in STF, pH 7.2 with 5 µl of SYPRO Orange dye (Invitrogen S-6651) diluted 40X in STF (pH 7.2) in a duplicate 96-well PCR plate. The plate was sealed and measurements were performed on a QuantStudio 7 Flex real-time PCR system (Applied Biosystems). Samples underwent an initial equilibration step at 25 °C for 2 m, followed by a temperature ramp to 99 °C in increments of 0.05 °C / s. Fluorescence emission was monitored using the FAM filter array. The Tm value for each sample was calculated using the Protein Thermal Shift software (Applied Biosystems) and the Boltzmann method. Petition 870260111560, dated 10 / 29 / 2026, pp. 78 / 219 74 / 92 Accelerated study of stability and thermal stress
[0213] For accelerated stability tests, samples were diluted to 1 mg / ml in STF, pH 7.2 and incubated for 2 weeks at 4 °C or 45 °C. Samples were then analyzed by HP-SEC. Monomer, aggregate, and fragment percentages for each sample were calculated based on curve integration using the HPLC ChemStation software (Agilent). The change in monomer, aggregate, and fragment content was calculated from the difference between each sample incubated at 45 °C versus 4 °C. Example 2 - Parental antibody construction
[0214] IgG1-TM AZ Vk + AZ VH was generated, which was evaluated for CD3+ cell binding, including ALL HPB (high-density human CD3+), Jurkat (human CD3+), Jurkat (human CD3-TCR KO), and HSC-F (high-density cynomolgus monkey CD3+) by flow cytometry measurement. The results are summarized in Figure 1. Figure 1 shows that IgG1-TM AZ Vk + AZ VH maintains the cross-reactivity of the parent antibody to human and cynomolgus monkey CD3 (Figures 1A and B) and exhibits selective binding to CD3+ cells, as demonstrated by a lack of binding to Jurkat TCR KO cells (see Figures 1C and D). Example 3 - mitigating liability in CDRs
[0215] Potential sequence imputabilities represent a risk for large-scale manufacturing. For example, NN and NG deamidation sites were found in CDR L1, a tryptophan oxidation site in CDR H1, and a DK isomerization site and an NS deamidation site in CDR H2. Therefore, initial CDR manipulation efforts focused on mitigating these imputabilities.
[0216] To mitigate the NN and NG deamidation sites in CDR L1, constructs were generated that mutated the NNG sequences to NQA or NTG where the underlined amino acids differ from the parental anti-CD3. In addition, constructs were generated that also mutated phenylalanine in CDR L2 to alanine or Petition 870260111560, dated 10 / 29 / 2026, p. 79 / 219 75 / 92 tyrosine, wherein alanine is present in the human germline IGKV2D-28*01 and tyrosine is a hydrophobic amino acid with a structure similar to phenylalanine.
[0217] Similarly, to mitigate the tryptophan oxidation site in the CDR H1 constructs were generated that mutated tryptophan to tyrosine. Additionally, constructs were generated that mutated threonine-lysine at the FW1-CDR H1 junction and histidine at the CDR H1 end to serine-asparagine and serine, respectively, which are present in the human IGHV3-15*02 germline. To mitigate potential imputabilities at CDR H2, DK was mutated to DR and NS to QS or QT.
[0218] Combinations of the Vk and VH variants were then generated and binding to HPB ALL (high human CD3+), Jurkat (human CD3+), Jurkat (TCR KO, human CD3-), and HSC-F (high CD3+ from cynomolgus monkeys) was assessed by flow cytometry measurement. The results are summarized in Figure 2, which shows that the variants exhibit a spectrum of affinities with human and cynomolgus monkey CD3+ cells; and, most importantly, the variants maintain binding to cynomolgus monkey CD3+ cells.
[0219] Candidates that maintained binding to CD3+ cells were prioritized and additionally identified variants that specifically modified CDR L3 and CDR H3 to confer desirable cytotoxicity, T cell activation and cytokine release profiles. Example 4 - Alanine scan of CDR L3 and CDR H3
[0220] To identify residues in CDR L3 and CDR H3 that were directly and indirectly involved in the anti-CD3 paratope, alanine scan mutagenesis of these regions was performed and the binding of variants to CD3+ cells was assessed by flow cytometry. The results were interpreted as follows: (1) variants that abolished binding to CD3+ cells contained mutations that disrupted the anti-CD3 paratope; (2) variants that exhibited decreased binding contained mutations that merely disrupted the paratope; (3) variants that exhibited unaffected binding contained mutations that were not involved in the paratope. Petition 870260111560, dated 10 / 29 / 2026, pp. 80 / 219 76 / 92
[0221] The results show that Vk variants containing G91A or F96A (Kabat numbering) abolished CD3+ cell binding, variants containing G89A, Q90A, T92A showed modestly decreased binding, and variants containing Q93A, Y94A, P95A, or T97A did not affect binding. Similarly, VH variants containing Y97A and A98L abolished CD3+ cell binding, while variants containing R93A, G94A, V95A, Y96A, P100aA, F100bA, or Y102A exhibited modestly decreased binding, and variants containing L99A, S100A, or D101A showed unaffected binding profiles. Example 5 - Functional characterization of anti-CD3 variants in a relevant bispecific format
[0222] Binding to CD3+ cells is only a prerequisite for T cell engager function, and the goal is to optimize the functional activity of the CD3-binding arm in the context of a relevant bispecific T cell engager. Therefore, monovalent bispecific antibodies were constructed based on the well-established DuetMab platform (Mazor et al., 2015; Wang et al., 2020; Dovedi et al., 2021) to determine the functional effects of anti-CD3 variants on affinity, cytotoxicity, T cell activation, and cytokine release. These DuetMabs were composed of anti-EGFR and anti-CD3 variant binding arms.
[0223] It is important to note that functional characterization of anti-CD3 variants was necessary to identify variants with adequate affinity, cytotoxicity, T-cell activation, and cytokine release. Finally, three light chain variants (AZ Vk 17, AZ Vk 26, and AZ Vk 29) and nine heavy chain variants (AZ VH R75, AZ VH R79, AZ VH R82, AZ VH SN75, AZ VH SN79, AZ VH SN82, AZ VH E75, AZ VH E79, and AZ VH E82) were chosen as the anti-CD3 variant composition for further investigation. The twenty-seven anti-CD3 variants derived from these Vk and VH combinations were extensively characterized.
[0224] The EGFR-CD3 variant DuetMabs were characterized for CD3+ cell binding affinity and functionally profiled for cytotoxicity, T cell activation, and cytokine release after exposure to Petition 870260111560, dated 10 / 29 / 2026, page 81 / 219 77 / 92 EGFR+ cells. To allow for direct comparisons, all functional assays were completed with a single batch of frozen peripheral blood mononuclear cells (PBMCs) to avoid the inherent donor-to-donor heterogeneity of freshly isolated PBMCs. The selected batch of PBMCs reflects the median reactivity of PBMCs investigated. Furthermore, functional activity was assessed for all variants using low-EGFR+ NCI H358 cells (3.1 x 10⁴ ± receptors / cell) (Mazor et al., 2017) and the selected variants using high-EGFR+ MDA-MB-468 receptors (1.1 x 10⁶ ± 2.8 x 10⁴ receptors / cell).
[0225] The results are shown in Figures 3 to 17. DuetMabs containing anti-CD3 variants exhibit variable affinity for CD3+ cells, cytotoxicity of EGFR+ cells, T cell activation, and cytokine release profiles. Furthermore, the functional responses elicited by the EGFR-CD3 variant DuetMabs were EGFR-dependent. For example, DuetMabs that exhibited very little activity after exposure to low-EGFR+ NCI H358 exhibited enhanced activity on high-EGFR+ MDA-MB-468. Therefore, the optimal anti-CD3 variant composition of T cell engagers can be selected based on the desired TAA density or TAA-CD3 format (1+1, 2+1, 1+1+1, etc.). Example 6 - Evaluation of T cell activation in the absence of target cells
[0226] T cell engagers based on anti-CD3 variants were evaluated for performance in the presence of EGFR+ target cells and T cells. However, it was also important to understand the behavior of T cell engagers containing anti-CD3 variants in the absence of EGFR+ cells, as premature T cell activation can lead to undesirable toxicities and cytokine release syndrome (CRS) in vivo.
[0227] In order to evaluate the level of T cell activation induced by the present T cell engagers containing anti-CD3 variants in the absence of EGFR+ cells, a plate-based CMSP incubation assay was used. In this assay, CMSPs were incubated in 96-well plates that were pre-coated Petition 870260111560, dated 10 / 29 / 2026, page 82 / 219 78 / 92 with varying concentrations of candidate T cell engagers (50, 5.0, 0.5 nM). After 48 hours of exposure, the activation level of CD4+ and CD8+ T cells was characterized by flow cytometry using CD25 and CD69 markers. The results are summarized in Figure 18 and indicate that all T cell engagers containing anti-CD3 variants exhibit reduced T cell activation compared to the anti-CD3-based control. Exemplo 7 - Medição cinética
[0228] The binding kinetics of variant anti-CD3 antibodies were determined using Octet analysis. The results are shown in Figure 19 and Table 2. The variants exhibited a 10- to 100-fold reduction in affinity for human CD3. Table 2: Kinetic measurements of the soluble form of CD3 were obtained using an Octet384 instrument. The dissociation constants, KD, were calculated as a ratio of kof / kon from a non-linear fit of the data. variante aCD3 Kd (M) Erro de Kd ka (1 / Ms) Erro de ka kdis (1 / s) Erro de kdis ΧΛ2 completo ΚΛ2 total Anti-CD3 parental 2.43E-08 1.89E-11 4.33E+04 2.39E+01 1.05E-03 5.78E-07 0.3325 0.9999 AZ Vk 17 + AZ VH R75 2.66E-07 9.61E-10 2.42E+04 4.84E+01 6.44E-03 1.93E-05 0.4807 0.9994 AZ Vk 17 + AZ VH R79 7.34E-07 1.60E-09 2.46E+04 4.51E+01 1.80E-02 2.13E-05 0.3476 0.9996 AZ Vk 17 + AZ VH R82 5.50E-07 1.52E-09 1.69E+04 3.12E+01 9.28E-03 1.90E-05 0.4113 0.9994 AZ Vk 17 + AZ VH SN75 8.53E-07 1.36E-09 1.08E+04 1.18E+01 9.23E-03 1.07E-05 0.1095 0.9998 AZ Vk 17 + AZ VH SN79 2.05E-06 6.69E-09 1.56E+04 4.25E+01 3.20E-02 5.73E-05 0.1498 0.9996 AZ Vk 17 + AZ VH SN82 1.64E-06 4.56E-09 9.10E+03 1.73E+01 1.49E-02 3.03E-05 0.0948 0.9998 AZ Vk 17 + AZ VH E75 2.79E-06 9.34E-09 7.10E+03 1.94E+01 1.98E-02 3.85E-05 0.1017 0.9997 AZ Vk 17 + AZ VH E79 5.62E-06 4.17E-08 8.85E+03 5.51E+01 4.97E-02 2.00E-04 0.1967 0.9991 AZ Vk 17 + AZ VH E82 4.61E-06 2.34E-08 7.14E+03 3.28E+01 3.30E-02 7.14E-05 0.0948 0.9995 AZ Vk 26 + AZ VH R75 2.17E-07 7.79E-10 2.79E+04 5.32E+01 6.05E-03 1.84E-05 0.5034 0.9994 AZ Vk 26 + AZ VH R79 7.12E-07 2.07E-09 3.27E+04 8.39E+01 2.33E-02 3.20E-05 0.5156 0.9992 AZ Vk 26 + AZ VH R82 4.11E-07 1.03E-09 1.73E+04 2.54E+01 7.11E-03 1.44E-05 0.3284 0.9996 AZ Vk 26 + AZ VH SN75 9.49E-07 2.84E-09 1.63E+04 3.09E+01 1.55E-02 3.59E-05 0.1873 0.9997 AZ Vk 26 + AZ VH SN79 1.93E-06 6.31E-09 1.87E+04 5.19E+01 3.61E-02 6.26E-05 0.1571 0.9996 AZ Vk 26 + AZ VH SN82 1.71E-06 4.44E-09 1.24E+04 2.43E+01 2.12E-02 3.63E-05 0.0922 0.9998 AZ Vk 26 + AZ VH E75 2.28E-06 4.23E-09 7.54E+03 1.05E+01 1.72E-02 2.10E-05 0.0403 0.9999 AZ Vk 26 + AZ VH E79 4.66E-06 5.20E-08 1.10E+04 1.06E+02 5.11E-02 2.86E-04 0.0884 0.9988 AZ Vk 26 + AZ VH E82 3.92E-06 1.70E-08 7.33E+03 2.79E+01 2.87E-02 5.88E-05 0.0846 0.9995 AZ Vk 29 + AZ VH R75 2.24E-07 4.97E-10 5.33E+04 8.83E+01 1.19E-02 1.76E-05 0.3829 0.9995 AZ Vk 29 + AZ VH R79 8.78E-07 5.08E-09 5.55E+04 2.82E+02 4.87E-02 1.35E-04 0.8738 0.9984, Petition 870260111560, de 29 / 10 / 2026, p. 83 / 219 79 / 92 AZ Vk 29 + AZ VH R82 5.95E-07 1.46E-09 3.88E+04 8.40E+01 2.31E-02 2.64E-05 0.4141 0.9994 AZ Vk 29 + AZ VH SN75 1.01E-06 3.03E-09 2.79E+04 7.63E+01 2.82E-02 3.44E-05 0.3159 0.9994 AZ Vk 29 + AZ VH SN79 2.67E-06 3.17E-08 4.28E+04 4.64E+02 1.14E-01 5.61E-04 0.2298 0.9976 AZ Vk 29 + AZ VH SN82 1.86E-06 5.97E-09 2.27E+04 6.33E+01 4.22E-02 6.76E-05 0.1423 0.9996 AZ Vk 29 + AZ VH E75 2.22E-06 9.28E-09 1.82E+04 6.59E+01 4.04E-02 8.41E-05 0.2000 0.9994 AZ Vk 29 + AZ VH E79 4.58E-06 6.12E-08 2.58E+04 3.20E+02 1.18E-01 5.91E-04 0.1327 0.9978 AZ Vk 29 + AZ VH E82 5.00E-06 6.23E-08 1.51E+04 1.70E+02 7.55E-02 4.02E-04 0.0926 0.9982 Example 8 - Capacity for development
[0229] Antibodies exhibiting inappropriate behavior have been correlated with low clinical success, and as a result, it has become increasingly common to identify and mitigate risks before candidate selection. For this purpose, anti-CD3 variants were further characterized regarding expression titer, nonspecific binding, reversible self-association, thermal stability, and propensity for aggregation and fragmentation after thermal stress. The results of these assessments are summarized in Table 3. Table 3: Summary of the developmental capacity profiles of EGFR-CD3 variant antibodies. Before biochemical, biophysical, and biological characterization, the antibodies were purified by protein A affinity chromatography followed by light chain affinity chromatography and then subjected to preparatory SEC for aggregate removal. ELISA BVP HEK AC-SINS DSF binding Accelerated stability (45 °C, 14μ) aCD3 variant BVP score BSA / Plaque binding Cell binding? STF (nm) HSA (nm) Õ O o õ c Õ O Monomer loss (%) Aggregate increase (%) Fragment increase (%) ΔPT of NIP228 (min) Parental anti-CD3 6.42 0.10 N 1.75 1.25 49.5 7 61.22 - 2.38 0.49 1.88 0.07 AZ Vk17 + AZ VH R75 3.85 0.06 N 1.75 2.25 52.0 2 61.18 - 3.71 0.59 3.12 0.07 AZ Vk17 + AZ VH R79 2.87 0.04 N 1.75 0.25 49.7 4 60.81 - 2.40 1.16 1.25 0.09 AZ Vk17 + AZ VH R82 2.87 0.05 N 1.75 0.75 50.4 5 61.2 3.18 0.83 2.35 0.06 Petition 870260111560, dated 10 / 29 / 2026, p. 84 / 219 80 / 92 AZ Vk17 + AZ VH SN75 2.06 0.03 N 1.25 0.75 50.2 7 61.57 - 1.67 0.00 1.67 0.06 AZ Vk17 + AZ VH SN79 2.75 0.04 N 1.75 0.75 50.0 9 61.09 - 1.72 0.35 1.37 0.08 AZ Vk 17 + AZ VH SN82 1.89 0.03 N 1.75 0.75 50.9 7 61.47 - 1.40 0.00 1.40 0.06 AZ Vk 17 + AZ VH E75 1.97 0.03 N 1.75 0.25 50.8 60.69 - 1.89 0.55 1.34 0.05 AZ Vk 17 + AZ VH E79 2.20 0.03 N 1.25 0.25 49.5 7 60.87 2.14 0.59 1.55 0.07 AZ Vk 17 + AZ VH E82 2.42 0.04 N 1.25 0.75 50.0 9 61.41 - 1.67 0.23 1.43 0.05 AZ Vk 26 + AZ VH R75 2.12 0.04 N 1.75 0.75 51.1 5 60.58 2.15 0.79 1.37 0.06 AZ Vk 26 + AZ VH R79 2.17 0.05 N 1.75 1.25 49.9 2 60.1 2.47 0.97 1.50 0.08 AZ Vk 26 + AZ VH R82 2.57 0.05 N 1.75 0.75 49.7 4 60.53 - 2.33 0.70 1.64 0.06 AZ Vk 26 + AZ VH SN75 1.68 0.03 N 1.25 0.75 50.7 9 61.2 1.81 0.24 1.56 0.06 AZ Vk 26 + AZ VH SN79 2.26 0.04 N 1.75 0.75 49.9 2 60.32 1.94 0.46 1.48 0.08 AZ Vk 26 + AZ VH SN82 2.27 0.04 N 1.75 1.25 50.2 7 60.72 1.31 0.00 1.31 0.06 AZ Vk 26 + AZ VH E75 1.64 0.03 N 1.75 0.75 50.4 5 60.3 - 3.40 1.20 2.20 0.05 AZ Vk 26 + AZ VH E79 2.08 0.04 N 1.75 1.25 50.9 7 59.85 5.45 3.34 2.11 0.07 AZ Vk 26 + AZ VH E82 3.07 0.05 N 0.75 1.25 50.6 2 60.33 4.80 2.58 2.22 0.05 AZ Vk 29 + AZ VH R75 5.64 0.07 N 1.75 0.75 49.3 9 60.46 - 6.13 2.83 3.30 0.07 AZ Vk 29 + AZ VH R79 3.08 0.04 N 1.75 0.25 50.2 7 60.34 - 3.20 1.45 1.74 0.10 AZ Vk 29 + AZ VH R82 2.61 0.04 N 1.75 0.75 50.0 9 60.58 - 4.43 1.80 2.63 0.07 AZ Vk 29 + AZ VH SN75 2.13 0.03 N 1.75 1.25 50.6 2 60.79 2.18 0.00 2.18 0.06 AZ Vk 29 + AZ VH SN79 3.08 0.05 N 1.75 1.25 49.9 2 60.36 - 3.27 1.05 2.22 0.08 AZ Vk 29 + AZ VH SN82 1.73 0.06 N 1.75 0.75 50.2 7 60.66 - 2.11 0.23 1.88 0.06, Petition 870260111560, de 29 / 10 / 2026, p. 85 / 219 81 / 92 AZ Vk 29 + AZ VH E75 1.82 0.03 N 1.25 0.75 49.9 2 60.59 3.00 1.56 1.44 0.05 AZ Vk 29 + AZ VH E79 2.12 0.03 N 1.25 0.75 50.0 9 60.21 - 3.83 1.65 2.18 0.07 AZ Vk 29 + AZ VH E82 1.67 0.03 N 1.75 0.75 49.9 2 60.46 1.86 0.44 1.42 0.05
[0230] DuetMabs containing a purified anti-CD3 variant exhibiting >95% correctly paired light chains and >98% monomers were fully characterized for nonspecific binding, reversible self-association, and thermal stability. To assess nonspecific binding, DuetMabs based on anti-CD3 variants were evaluated using a baculovirus particle ELISA (BVP) and a human embryonic kidney 293 (HEK293) cell binding assay by flow cytometry. CD3 is not expressed in the insect cells used to generate the baculovirus particles nor in HEK293; instead, these assays assess the 'viscosity' of the tested antibody. The present evaluation of the parental antibody showed a modest risk of nonspecific binding to baculovirus particles but showed no nonspecific binding to HEK293 cells.In assays evaluating the nonspecific binding of anti-CD3 variants, only the AZ Vk 29 + AZ VH R75 variant showed a risk of nonspecific binding, where the pattern (nonspecific binding to baculovirus particles, but not HEK293) was similar to the parental antibody, although at lower levels. Subsequently, the thermal stability of anti-CD3 variants was evaluated by differential scanning fluorimetry. Both the parental antibody and all anti-CD3 variants exhibited melting temperatures (Tm) of approximately 61 °C with temperatures at the onset of melting (Tinitial) of ~49 to 50 °C.
[0231] In addition to these developmental capacity assessments, the anti-CD3 variants were evaluated in an accelerated stability study, in which antibodies were incubated at 45 °C for 14 days and pre- and post-thermal stress samples were assessed for fragmentation and aggregation. Example 9 - Multispecific antibodies containing charge pairs
[0232] To improve correct chain pairing beyond what alternative disulfides can achieve in the DuetMab configuration (see document no. Petition 870260111560, dated 10 / 29 / 2026, page 86 / 219 82 / 92 WO 2013 / 096291 (incorporated herein by reference), the charge pairs were designed using amino acids that participate in the lambda light chain (LC) - heavy chain (HC) interface. The following positions were evaluated as lambda light chain amino acids that participate in interface formation with the CH1 domain: T117, F119, S122, E124, E125, K130, T132, V134, L136, S138, D139, E161, T163, S166, Q168, A174, S176, Y178, S180, together with the following heavy chain CH1 domain amino acids that participate in interface formation with the lambda light chain CL domain: S124, F126, L128, A129, S131, S132, K133, S134, A141, G143, L145, K147, D148, H168, F170, P171, V173, Q175, S176. S181, S183, V185, T187, V211, K213.
[0233] These amino acids were explored in pairs or alone, one pair at a time or in combinations, with alternative interchain disulfides or maintaining native disulfides. The introduction of positively or partially positively charged amino acids means replacing the existing amino acids in that position with lysine and arginine and, in some cases, with asparagine or glutamine or histidine. The introduction of negatively or partially negatively charged amino acids means replacing the existing amino acids in that position with aspartic acid, glutamic acid, serine, threonine and, in some cases, with asparagine or glutamine. The addition of a histidine residue in some of these positions will allow the introduction of a pH-dependent CH1-CL interaction.
[0234] Nine sets of pair matchings on the LC lambda-HC interface that meet the above criteria are provided in Table 4 as a non-exhaustive example and have been tested for enhanced matching in this descriptive report.
[0235] Table 4. All mutations presented here are specific for molecules containing lambda light chains and are expected to function as lambda charge pairs. Furthermore, opposite charge pairs [i.e., V134(D, E, S, T) - L128 (R, K, H)] are expected to provide preferential pairing. Net-uncharged side-chain amino acids, such as asparagine and glutamine, can be used for Petition 870260111560, dated 10 / 29 / 2026, p. 87 / 219 83 / 92 substitutions for those that have a partial positive or negative charge, since it has been found that they participate in the formation of hydrogen bonds with both positively and negatively charged amino acids, as well as with each other. Conjunto CÀ (+) CH1(-) n° 1 V134 (R,K,H) L128 (D,E,S,T) n° 2 V134 (R,K,H) L145 (D,E,S,T) n° 3 L136 (R,K,H) V185 (D,E,S,T) n° 4 T117 (R,K,H) V185 (D,E,S,T) n° 5 T117 (R,K,H) A141 (D,E,S,T) n° 6 F119 (R,K,H) L128 (D,E,S,T) n° 7 Y178 (R,K,H) V173 (D,E,S,T) n° 8 V134 (R,K,H) S183 (D,E,T) n° 9 T117 (R,K,H) T187 (D,E)
[0236] For the construction of DuetMab antibodies with charge-pair mutations at the heavy-chain-light-chain interface, the pDuet-Heavy and pDuet-Light plasmids described in (WO 2013 / 096291 and in Mazor et al. mAbs 2015) were used as main chain vectors. Briefly, the pDuet-Heavy vector contained two human gamma1 heavy chain (HC) cassettes to support HC heterodimerization, wherein the first heavy chain carried the Hole mutation set (T366S / L368A / Y407V) and a stabilizing mutation (Y349C) in the CH3 domain, while the latter carried the complement Knob mutation (T366W) and a stabilizing mutation (S354C) in CH3, although the cassette order could be readily reversed. The pDuet-Light vector contained two human light chain (LC) cassettes, where the first light chain carried a kappa constant domain (Ck), while the latter carried a lambda constant domain (CA).The pDuet-Heavy and pDuet-Light vectors also contained mutations to remove the native interchain disulfide bond at CH1 / CA and provide the alternative disulfide bond that is denoted as V12 DS or V12 in this case. Petition 870260111560, dated 10 / 29 / 2026, pp. 88 / 219 84 / 92 descriptive report, in which the F126C / C220V mutations were introduced into the CH1 domain of the Knob heavy chain and the S122C / C212V mutations were introduced into the lambda constant domain. The amino acid sequences of the constant domains in the DuetMab antibody main chains exemplified (before the introduction of charge mutations) are provided as follows:
[0237] The Knob-and-Hole set mutations and stabilizing / alternative disulfide bonds used herein are provided only as an example. One skilled in the art may use any other combinations of mutations for the Knob-and-Hole technique and / or stabilizing / alternative disulfide bonds known in this field to support HC heterodimerization.
[0238] For the construction of the pDuet-Heavy vector with charge mutations, the Hole heavy chain was cloned into the pDuet-Heavy vector from a synthesized DNA fragment of VH-CH1-CH2-CH3 domains containing the aforementioned mutations for the Hole heavy chain using the BssHII / HindIII restriction cloning technique. Optionally, the Hole heavy chain contained the S183K charge mutation in the CH1 domain. The Knob heavy chain was cloned into the vector from a synthesized DNA fragment of VH-CH1-CH2-CH3 domains containing the aforementioned mutations for the Knob heavy chain using the BsrGI / EcoRI restriction cloning technique. Optionally, the Knob heavy chain contained one of the following charge mutations in the CH1 domain: L128D, L128E, L128S, L128T, A141D, A141E, A141S, A141T, L145D, L145E, L145S, L145T, S183D, V185D, V185E, V185S, V185T, V173D, V173E, V173S, and V173T.
[0239] For the construction of pDuet-Light with charge mutations, the kappa light chain was cloned into the pDuet-Light vector from a DNA fragment synthesized from VL-Ck domains using the BssHII / NheI restriction cloning technique. Optionally, the constant kappa domain (Ck) contained the V133E charge mutation. The lambda light chain was cloned into the pDuet-Light vector from a DNA fragment synthesized from VL-Cα domains containing the S122C / C212V mutations above. Petition 870260111560, dated 10 / 29 / 2026, pp. 89 / 219 85 / 92 mentioned for the lambda light chain using the restriction cloning technique by BsrGI / EcoRI. Optionally, the constant lambda domain (Cλ) contained one of the following charge mutations: V117R, V117K, F119R, F119K, V134R, V134K, L136R, L136K, Y178R, and Y178K. The variable light chain domain (VL) could be the variable kappa domain (Vk) or the variable lambda domain (νλ).
[0240] All constructs were temporarily expressed in CHO cells in suspension using PEI-MAX (Polysciences, Inc., Warrington, PA) as a transfection reagent and cultured in an internally produced CHO medium. Vectors containing the following charge pair combinations were used for antibody expression in these studies. A schematic of the constructed DuetMabs containing charge pairs is provided in Figure 20. Table 5 below provides details of several CD3- and EGFR-targeted lambda charge pair DuetMabs that were produced. Table 5. Details of EGFR / CD3 DuetMabs produced containing lambda charge pairs. Sample No. pDuet-Heavy pDuet-Light Heavy chain hole Heavy chain knob Light chain kappa Light chain lambda Target CH1 Target CH1 (V12) Target CL Target CL (V12) 1 EGFR WT CD3 WT EGFR WT CD3 WT 2 EGFR S183K CD3 WT EGFR V133E CD3 WT 33 EGFR S183K CD3 A141D EGFR V133E CD3 T117R 34 EGFR S183K CD3 A141E EGFR V133E CD3 T117R 35 EGFR S183K CD3 A141S EGFR V133E CD3 T117R 36 EGFR S183K CD3 A141T EGFR V133E CD3 T117R 41 EGFR S183K CD3 A141D EGFR V133E CD3 T117K
[0241] Culture medium was collected 7 to 13 days after transfection and filtered through a sterile 0.22 μm filter. Antibody concentration in culture supernatants was measured using an Octet384 instrument with protein A sensors (Sartorius, Göttingen, Germany) according to the manufacturer's protocol. Antibodies were purified by protein A magnetic microsphere affinity purification (Genscript, Piscataway, NJ, USA) or Petition 870260111560, dated 10 / 29 / 2026, pp. 90 / 219 86 / 92 standard protein A affinity chromatography (Cytiva, Marlborough, MA, USA) was used, followed by light chain affinity chromatography, if necessary, according to the manufacturer's protocol, and subsequently exchanged for buffer in STF (pH 7.2). The purity and oligomeric state of purified molecules were determined by microfluidic electrophoresis and size exclusion chromatography (see methods below). Protein aggregates were removed by preparative SEC. Concentrations of purified antibodies were determined by absorbance reading at 280 nm using theoretically determined extinction coefficients.
[0242] Analytical SEC-HPLC (Agilent 1260 Infinity HPLC system) was performed using a TSK-gel G3000SWxL column (Tosoh Biosciences, King of Prussia, PA) to determine the oligomeric state of purified molecules. Preparatory SEC-HPLC was performed using a Superdex 200 column (Cytiva) to remove protein aggregates.
[0243] Microfluidic-based electrophoresis was performed using A bioanalyzer was used according to the manufacturer's protocol (Agilent, Santa Clara, CA) to evaluate the kappa-to-lambda light chain ratio of an antibody, based on which the correct light chain ratio percentage was calculated.
[0244] Table 6 summarizes the expression and biochemical profiles of selected charge pair variants in DuetMabs EGFR / CD3. Charge pair variants #33, #34, #35, #36 and #41 showed improved correct LC ratio compared to controls #1 and #2. Table 6: Summary of the expression and biochemical profiles of selected charge pair variants in DuetMabs EGFR / CD3. DuetMab Sample No. Arm hole Arm knob Day 10 / 12 Title (pg / ml) % Correct LC Ratio % Monomers CH1 Ck CH1 (V12) Cλ (V12) EGFR / CD3 1 WT WT WT WT 364.2 38.2 94.8 2 S183K V133E WT WT 313.6 66.4 97.3 33 S183K V133E A141D T117R 289.9 89.8 96.5 Petition 870260111560, dated 10 / 29 / 2026, pp. 91 / 219 87 / 92 34 S183K V133E A141E T117R 365.5 93.6 96.2 41 S183K V133E A141D T117K 252.7 92.1 97.1 Example 10 - Generation of 2+1 bispecific antibodies containing lambda charge pairs
[0245] The p2 +1-Heavy vector was constructed on the pDuet-Heavy main strand described in Example 9. For the construction of the p2 +1-Heavy vector with charge mutations, the Hole heavy strand was cloned into the vector by BssHII / HindIII, as previously described. The Knob heavy strand was cloned into the vector from a DNA fragment synthesized from VH-CH1-VH-CH1-CH2-CH3 domains using the restriction cloning technique by BsrGI / EcoRI, where the preceding VH-CH1 segment corresponded to the sequence found in the Hole heavy strand and the subsequent VH-CH1 segment contained the VH against another target, as well as the A141D and V12 DS charge mutations in CH1. The pDuet-Light vector is common to the bispecific Duet2 (2+1) and DuetMab constructs.
[0246] All bispecific Duet2 (2+1) constructs were temporarily expressed and purified as described above for DuetMab molecules.
[0247] A schematic of the constructed Duet2 (2+1) containing load pairs is provided in Figure 21.
[0248] Table 7 summarizes the expression and biochemical profiles of bispecific molecules EGFR / CD3 and NIP228 / CD3 Duet2 (2+1) carrying the selected sets of charge pairs produced in 500 ml cell culture. NIP228 is a non-specific control binding domain. For further analysis, the DuetMabs were additionally purified by light chain affinity chromatography to remove mismatched byproducts and aggregates were removed by preparative SEC. Table 7: Production of bispecific Duet2 (2+1) with charge mutations._________ Duet2 (2+1) bispecific Antigen 1 / NIP228 (hole arm) Antigen 1 / NIP228 (knob arm) CD3 (knob arm) Titer (ug / ml) Profiles after protein A purification Profiles after light chain purification Petition 870260111560, dated 10 / 29 / 2026, pp. 92 / 219 88 / 92 CH1 Ck CH1 Ck CH1 (V12) Cλ (v12) Di a 7 Dia 14 Kappa and lambd ratio at % monomer s Kappa and lambd ratio at % monomer os Endotoxin (EU / mg) EGFR / CD3 2+1 S183 K V133 E S183 K V133 E A141 D T117 R 55 13 0 2.49: 1 90 2:1 >99 <0.5 NIP228 / CD3 2+1 S183 K V133 E S183 K V133 E A141 D T117 R 96 38 0 2.39: 1 91 1.9:1 >99 <0.5
[0249] Table 8 summarizes the thermal stabilities of bispecific molecules EGFR / CD3 and NIP228 / CD3 Duet2 (2+1) were analyzed by differential scanning fluorimetry (DSF) and their accelerated stability profiles were determined. The bispecific Duet2 (2+1) molecules did not show signals for aggregation or fragmentation after thermal stress. Table 8: Summary of development capabilities of bispecific Duet2 (2+1) with Duet2 (2+1) bispecific charge mutations Accelerated stability (45 °C, 14D) DSF Monomer loss (%) Aggregate increase (%) Fragment increase (%) ΔRT of NIP228 (m) Initial Tm Tm EGFR / CD3 2+1 6.18 0.30 5.87 6.18 50 60.6 NIP228 / CD3 2+1 3.19 0.69 2.49 3.19 47 58.3
[0250] Table 9 shows the subunit mass spectrum data of the bispecific molecules EGFR / CD3 and NIP228 / CD3 Duet2 (2+1). The alignment of theoretical and measured mass confirmed the integrity of the molecule and the LC / HC association identity of each variant. Table 9: MS results from LC / MS subunit analysis EGFR / CD3 2+1 measured mass theoretical mass Fc with 2 G0F 53095 53095 Fab LC of antigen 1 + HC of antigen 1 (Hole arm) 47545 47544 Fab LC of antigen 1 + HC of antigen 1 + Fab LC CD3 + HC CD3 (Knob arm) 95876 95876 NIP228 / CD3 2+1 measured mass theoretical mass Fc with 2 G0F 53095 53095 Fab NIP228-LC + NIP228 HC (Hole arm) 46991 46991 Petition 870260111560, dated 10 / 29 / 2026, pp. 93 / 219 89 / 92 Fab NIP228 LC + NIP228 HC + Fab CD3 LC + CD3 HC (Knob arm) 95322 95322
[0251] Table 10 shows the thermal stability studies of bispecific molecules EGFR / CD3 and NIP228 / CD3 Duet2 (2+1) using differential scanning calorimetry (DSC) analysis. Table 10 lists the deconvoluted TM and approximate Tiniti values of bispecific molecules Duet2 (2+1). Table 10: MS results from LC / MS subunit analysis Name Tmi (°C) TM2 (°C) TM3 (°C) Approximate Tmi (°C) ± SD EGFR / CD3 Duet2 (2:1) 64.6 70.5 79.0 51.8 ± 0.4 NIP228 / CD3 Duet2 (2:1) 66.7 71.8 79.3 53 ± 1.3
[0252] The bispecific EGFR / CD3 Duet2 (2+1) molecules were tested in a cytotoxicity assay containing T cells and target cells expressing EGFR and activated CD8 and CD4 T cells, demonstrating that this Duet2 (2+1) is functional. Example 11 - Generation of trispecific antibodies containing lambda and kappa charge pairs
[0253] The pTriMab-Heavy vector was constructed on the pDuetHeavy main strand described in Example 9 above. For the construction of the pTriMab-Heavy vector with charge mutations, the Hole heavy strand was cloned into the vector by BssHII / HindIII as previously described, where the VH-CH1 segment in the Hole heavy strand was defined as Fab1 with VH against a first target and the S183K charge mutation in CH1. The Knob heavy strand was cloned into the vector from a DNA fragment synthesized from VH-CH1-VH-CH1-CH2-CH3 domains using the restriction cloning technique by BsrGI / EcoRI. The previous VH-CH1 segment of the Knob heavy strand was defined as Fab2 with VH against a second target, as well as the S183E charge mutation and, optionally, DS V12 in CH1. The subsequent VH-CH1 segment of the Knob heavy chain was defined as Fab3 with VH against a third target, as well as the A141D payload mutation and DS V12 in CH1. Petition 870260111560, dated 10 / 29 / 2026, pp. 94 / 219 90 / 92
[0254] The pTriMab-Light1 and pTriMab-Light2 vectors were constructed on the pDuet-Light main chain described in Example 1 above. For the construction of pTriMab-Light1 with charge mutation, the kappa light chain for Fab1 was cloned into the vector by BssHII / NheI, as previously described, where the Ck domain contained the V133E charge mutation. The second LC (lambda) cassette in pTriMabLight1 was removed.
[0255] For the construction of pTriMab-Light2 with charge mutations, the kappa light chain for Fab2 was cloned into the vector by BssHII / NheI, as previously described, where the Ck domain contained the V133K charge mutation and optionally the V12 DS (S121C / C214V for Ck). The lambda light chain for Fab3 was cloned into the vector by BsrGI / EcoRI, as previously described, where the Cã domain contained the T117R charge mutation and the V12 DS.
[0256] All TriMab constructs were temporarily expressed and purified as described above for DuetMab molecules. A schematic of the constructed TriMabs containing charge pairs is provided in Figure 22.
[0257] Table 11 summarizes the expression and biochemical profiles of TriMab EGFR / Her2 / CD3 loading the selected sets of charge pairs produced in 500 ml of cell culture. For further analysis, the TriMabs were additionally purified by protein A affinity chromatography and the aggregates were removed by preparative CHT column chromatography (an incompressible mixed-mode chromatography medium using cation exchange and calcium affinity interactions).
[0258] Table 11: TriMab EGFR / Her2 / CD3 trispecific with charge mutations. The kappa-to-lambda ratio was calculated by band density from capillary gel electrophoresis under reducing conditions using an Agilent Protein 80 Chip. Monomer content was calculated by intact size exclusion chromatography. Hydroxyapatite ceramic CHT is a mixed-mode purification method. TriMab Fab1-HER2 (Hole arm) Fab2-EGFR (Knob arm) Fab3-CD3 (Knob arm) Titer (pg / ml) Profiles after protein purification A Profiles after CHT Petition 870260111560, dated 10 / 29 / 2026, pp. 95 / 219 91 / 92 CH1 Ck CH1(v12) CK(v12) CH1 (v12) CA (v12) Day 12 Kappa and lambd ratio at % of s monomer Kappa and lambd ratio at % of s monomer EGFR / HER2 CD3 TriMab S183 K V133 E S183E V133K A141 D T117 R 176 2.12 95 2.41 >99
[0259] Table 12 summarizes the thermal stabilities of TriMab EGFR / Her2 / CD3 by differential scanning fluorimetry (DSF) and its accelerated stability profiles. The TriMab EGFR / Her2 / CD3 molecule did not show signals for aggregation or fragmentation after thermal stress.
[0260] Table 12: Summary of the developmental capacity of TriMab EGFR / Her2 / CD3 with charge mutations. The kappa-to-lambda ratio was calculated by band density from capillary gel electrophoresis under reducing conditions using an Agilent Protein 80 Chip. Monomer content was calculated by analytical chromatography by intact size exclusion._____________________ Molecule Name Accelerated Thermal Stability (45 °C, 14D) DSF Monomer Loss (%) Aggregate Increase (%) Fragment Increase (%) Tm(°C) Tinitius (°C) EGFR / HER2 CD3 TriMab 2.21 0 2.21 60.6 54.1
[0261] Table 13 reports the subunit mass spectrum data of TriMab EGFR / Her2 / CD3. The alignment of theoretical and measured mass confirmed the integrity of the molecule and the LC / HC association identity of each peak. Table 13: MS results of LC / MS analysis of TriMab subunit EGFR / Her2 / CD3. Peak Measured Mass (Da) Theoretical Mass (Da) Annotation 1 23588 23589 Antigen 2 LC+Cys 2 53096 53096 Fc (2xG0F) 53126 53128 Fc (2xG0F)+Trisulfide 3 50205 50205 Fc (non-glycan) 51650 51650 Fc(1xG0F) 4 100680 100677 Fab(Antigen 2)+Fc 100710 100709 Fab(Antigen 2)+Fc+Trisulfide 5 47599 47599 Fab(Antigen 2) Petition 870260111560, dated 10 / 29 / 2026, pp. 96 / 219 92 / 92 6 148953 148951 Fab(Antigen 1- CD3)+Fc+Trisulfide 7 95842 95841 Fab(Antigen 1-CD3)
[0262] Table 14 reports the thermal stability studies of TriMab EGFR / Her2 / CD3 using differential scanning calorimetry (DSC) analysis and lists the deconvoluted TM and approximate Tinitial values of TriMab EGFR / Her2 / CD3. Table 14: DSC thermostability measurements captured transitions to the Fab, CH1, CH2, and CH3 domains under the descriptions Tm1, Tm2, and Tm3. Some Transitions are summed at the same peak transition Tm Name TM1 (°C) TM2 (°C) Tm3 (°C) Total enthalpy (kcal / mol) FIO Approximate initial temperature (°C) ± sd EGFR / HER2 CD3 TriMab 64.0 68.3 77.0 1549.74 49.6 ± 3.1
[0263] TriMab EGFR / Her2 / CD3 molecules were tested in a cytotoxicity assay containing T cells and cells that were either EGFR-positive only (single-positive cells) or EGFR and HER2-positive (double-positive cells). TriMab EGFR / Her2 / CD3 showed cell killing, activation of CD8 and CD4 T cells from single-positive and double-positive cells, demonstrating that this TriMab format is functional. Petition 870260111560, dated 10 / 29 / 2026, pp. 97 / 219
Claims
1 / 11 CLAIMS 1. An antibody characterized by comprising an antigen-binding domain capable of binding to a CD3 protein or a fragment thereof, wherein the CD3 antigen-binding domain comprises a variable heavy chain (VH) region according to any of the following: a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:90; HCDR2 with the amino acid sequence of SEQ ID NO:91; and HCDR3 with the amino acid sequence of SEQ ID NO:92; a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:82; HCDR2 with the amino acid sequence of SEQ ID NO:83; and HCDR3 with the amino acid sequence of SEQ ID NO:84; a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:78; HCDR2 with the amino acid sequence SEQ ID NO: 79;and HCDR3 with the amino acid sequence of SEQ ID NO:80, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:66; HCDR2 with the amino acid sequence of SEQ ID NO:67; and HCDR3 with the amino acid sequence of SEQ ID NO:68, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:70; HCDR2 with the amino acid sequence of SEQ ID NO:71; and HCDR3 with the amino acid sequence of SEQ ID NO:72, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:74; HCDR2 with amino acid sequence SEQ ID NO: 75; and HCDR3 with amino acid sequence SEQ ID NO: 76, Petition 870260111560, dated 10 / 29 / 2026, page 98 / 219 2 / 11 a VH region comprising the following CDRs: HCDR1 with amino acid sequence SEQ ID NO: 86; HCDR2 with amino acid sequence SEQ ID NO: 87;and HCDR3 with the amino acid sequence of SEQ ID NO:88, a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:94; HCDR2 with the amino acid sequence of SEQ ID NO:95; and HCDR3 with the amino acid sequence of SEQ ID NO:96, and a VH region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:98; HCDR2 with the amino acid sequence of SEQ ID NO:99; and HCDR3 with the amino acid sequence of SEQ ID NO:100, and the CD3 antigen-binding domain comprising a variable heavy chain (VH) region according to any of the following: a VL region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO:46; HCDR2 with amino acid sequence SEQ ID NO: 47; and HCDR3 with amino acid sequence SEQ ID NO: 48, a VL region comprising the following CDRs: HCDR1 with amino acid sequence SEQ ID NO: 58; HCDR2 with amino acid sequence SEQ ID NO: 59;and HCDR3 with the amino acid sequence of SEQ ID NO: 60, and a VL region comprising the following CDRs: HCDR1 with the amino acid sequence of SEQ ID NO: 62; HCDR2 with the amino acid sequence of SEQ ID NO: 63; and HCDR3 with the amino acid sequence of SEQ ID NO:
64.
2. Antibody according to claim 1, characterized in that the CD3 antigen-binding domain comprises a VH region and a VL region comprising one of the following sets of CDRs: Petition 870260111560, 2026-10-29, p. 99 / 219 3 / 11 vii. HCDR1 with amino acid sequence SEQ ID NO: 90, viii. HCDR2 with amino acid sequence SEQ ID NO: 91, ix. HCDR3 with amino acid sequence SEQ ID NO: 92, x. LCDR1 with amino acid sequence SEQ ID NO: 46, xi. LCDR2 with amino acid sequence SEQ ID NO: 47 xii. LCDR3 with amino acid sequence SEQ ID NO: 48; or vii. HCDR1 with amino acid sequence SEQ ID NO: 82, viii. HCDR2 with amino acid sequence SEQ ID NO: 83, ix. HCDR3 with amino acid sequence SEQ ID NO: 84, x. LCDR1 with amino acid sequence SEQ ID NO: 46, xi. LCDR2 with amino acid sequence SEQ ID NO: 47, xii. LCDR3 with amino acid sequence SEQ ID NO: 48; or vii.HCDR1 with amino acid sequence SEQ ID NO: 78 viii. HCDR2 with amino acid sequence SEQ ID NO: 79 ix. HCDR3 with amino acid sequence SEQ ID NO: 80, x. LCDR1 with amino acid sequence SEQ ID NO: 62, xi. LCDR2 with amino acid sequence SEQ ID NO: 63, xii. LCDR3 with amino acid sequence SEQ ID NO:
64.
3. Antibody, according to claim 1 or claim 2, characterized in that the CD3 antigen-binding domain comprises a VH region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 77, SEQ ID NO: 89 or SEQ ID NO:
81.
4. Antibody, according to any of the preceding claims, characterized in that the CD3 antigen-binding domain comprises a VL region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 45 or SEQ ID NO: 61.
5. Antibody, according to any of the preceding claims, characterized by the CD3 antigen-binding domain comprising: Petition 870260111560, dated 10 / 29 / 2026, p.100 / 219 4 / 11 a VH region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 77, and a VL region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 61; a VH region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 89, and a VL region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 45 or a VH region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 81, and a VL region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO:
45.
6. An antibody, according to any of the preceding claims, characterized in that the CD3 antigen-binding domain binds to human CD3 with an affinity that has a Kd that is: i. between 10 times and 200 times greater; ii. between 15 times and 200 times greater; iii. between 20 times and 200 times greater; or iv. between 25 times and 200 times greater compared with the Kd of a control antigen-binding domain that binds to human CD3, with the control antigen-binding domain having a VH domain sequence of SEQ ID NO: 5 and a VL domain sequence of SEQ ID NO:
1.
7. Antibody, according to any of the preceding claims, characterized in that the CD3 antigen-binding domain exhibits reduced off-target T cell activity compared to a control antigen-binding domain, wherein the control antigen-binding domain has a VH domain sequence of SEQ ID NO: 5 and a VL domain sequence of SEQ ID NO: 1, optionally wherein off-target T cell activation is determined in a T cell activation assay in the absence of engagement with a target cell.
8. An antibody, according to any of the preceding claims, characterized by additionally comprising a target antigen-binding domain.
9. Antibody according to claim 8, characterized in that the target antigen-binding domain is capable of binding to a tumor-associated antigen (TAA).
10. Antibody, according to claim 9, characterized in that the TAA is selected from the list consisting of AFP, anb3 (vitronectin receptor), anb6, B-cell maturation agent (BCMA), CA125 (MUC16), CD4, CD20, CD22, CD33, CD52, CD56, CD66e, CD80, CD140b, CD227 (MUC1), EGFR (HER1), EpCAM, ganglioside GD3, HER2, prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), CD5, CD19, CD21, CD25, CD37, CD30, CD33, CD45, HLA-DR, anti-idiotype, carcinoembryonic antigen (CEA), for example, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), TAG-72, folate-binding protein, A33, G250, ferritin, glycolipids such as gangliosides, carbohydrates such as CA-125, IL-2 receptor, fibroblast-activating protein (FAP), IGF1R, B7H3, B7H4, PD-L1, CD200, EphA2, c-Met, and mesothelin.
11. Antibody, according to claim 9, characterized in that TAA is EGFR, HER2, STEAP2, GPC3 and c-Met.
12. Antibody, according to any one of claims 8 to 11, characterized by one of the antigen-binding domains comprising a CH1 region and a lambda constant (CLλ), optionally wherein the CD3 antigen-binding domains comprise the CH1 and CLλ regions.
13. Antibody according to claim 12, characterized in that CLλ has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity with SEQ ID NO:
105. Petition 870260111560, dated 10 / 29 / 2026, p. 102 / 219 6 / 11 14. Antibody according to claim 12 or claim 13, characterized in that the antigen-binding domains comprising the CLA region comprise a pair of lambda charges, optionally the pair of lambda charges being situated in one or more of the following pairs of positions in the antigen-binding domain: (i) position 117 in CLA and position 141 in CH1; (ii) position 117 in CLA and position 185 in CH1; (iii) position 119 in CLA and position 128 in CH1; (iv) position 134 in CLA and position 128 in CH1; (v) position 134 in CLA and position 145 in CH1; (vi) position 134 in CLA and position 183 in CH1; (vii) position 136 in CLA and position 185 in CH1; (viii) position 178 in CLA and position 173 in CH1;and (ix) position 117 in CLA and position 187 in CH1, wherein the lambda charge pair comprises a positively charged amino acid residue optionally selected from arginine, lysine or histidine situated in one of the positions in the lambda charge pair and a negatively charged amino acid residue optionally selected from aspartic acid, glutamic acid, serine or threonine situated in the other position in the lambda charge pair, and wherein the numbering is in accordance with the EU index.; 15. Antibody, according to claim 14, characterized in that the lambda charge pair is located at position 117 on CLA and at position 141 on CH1, optionally the lambda charge pair is selected from the following list: a. arginine at position 117 of CLA and aspartic acid at position 141 of CH1; b. arginine at position 117 of CLA and glutamic acid at position 141 of CH1; c. arginine at position 117 of CLA and serine at position 141 of CH1; Petition 870260111560, dated 10 / 29 / 2026, page 103 / 219 7 / 11 d. arginine at position 117 of CLλ and threonine at position 141 of CH1; and e. Lysine at position 117 of CLλ and aspartic acid at position 141 of CH1.
16. Antibody, according to any one of claims 12 to 15, characterized in that the other antigen-binding domain comprises a CH1 region and a CLk region, kappa constant, optionally wherein the target antigen-binding domains comprise the CH1 and CLk regions.
17. Antibody, according to claim 16, characterized in that CLk has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity with SEQ ID NO:
106.
18. Antibody, according to claim 16 or claim 17, characterized in that the antigen-binding domains comprising the CLk region comprise a pair of kappa charges, optionally the pair of kappa charges being situated at position 133 in CLk and at position 183 in CH1.
19. Antibody according to any one of claims 8 to 18, characterized in that: (i) the disulfide bond between the light chain and the CH1 in the CD3 antigen-binding arm is formed between a pair of manipulated cysteines in the light chain and the CH1 of the CD3 antigen-binding arm, and the disulfide bond between the light chain and the CH1 in the target antigen-binding arm is formed between a pair of native cysteines; or (ii) the disulfide bond between the light chain and the CH1 in the target antigen-binding arm is formed between a pair of manipulated cysteines in the light chain and the CH1 of the target antigen-binding arm, and the disulfide bond between the light chain and the CH1 in the CD3 antigen-binding arm is formed between a pair of native cysteines.
20. Antibody according to claim 21, characterized in that the pair of manipulated cysteines in the light chain and in the CH1 of the CD3 antigen-binding arm is located at position 122 of the light chain and at position 126 of the CH1 of the CD3 antigen-binding arm, and in that the light chain of the CD3 antigen-binding arm comprises a non-cysteine residue at position 212 and the CH1 of the CD3 antigen-binding arm comprises a non-cysteine residue at position 220, optionally the non-cysteine residues are valines.
21. Antibody, according to any one of claims 8 to 20, characterized in that the CD3 antigen-binding region additionally comprises a first Fc region and the target antigen-binding arm additionally comprises a second Fc region.
22. Antibody, according to claim 21, characterized by comprising modifications in the first and second Fc regions to facilitate heterodimerization of the first and second Fc regions.
23. Antibody according to claim 22, characterized in that the modifications are located in the CH3 of the Fc regions.
24. Antibody, according to claim 23, characterized in that the modification in the CH3 of one of the first and second Fc regions is a substitution of an amino acid residue for one with a longer side chain, thus generating a knob on the surface of said CH3 domain, and the modification in the CH3 of the other Fc region is a substitution of an amino acid residue for one with a shorter side chain, thus generating a hole on the surface of said CH3 domain, optionally the CH3 domain containing the knob being part of the first heavy chain polypeptide and the CH3 domain containing the hole being part of the second heavy chain.
25. Antibody according to claim 24, characterized in that the substitution to generate a knob is a tryptophan substitution at position 366 and the substitution to generate a hole is one or more of the following: i) a valine substitution at position 407; ii) a serine substitution at position 366; and iii) an alanine substitution at position 368.
26. Antibody, according to claim 24 or claim 25, characterized in that the CH3 domain containing the knob comprises a cysteine at position 354 and the CH3 domain containing the hole comprises a cysteine at position 349.
27. Antibody, according to any one of claims 21 to 26, characterized in that at least one of the Fc regions comprises the amino acid substitutions: (a) L234F / L235E / P331S; (b) E233P / L234V / L235A / G236del / S267K; and / or (c) M252Y / S254T / T256E.
28. Antibody, according to any one of claims 8 to 27, characterized by comprising two antigen-binding domains that are capable of binding to the same target.
29. Antibody according to claim 28, characterized by further comprising a CD8 antigen-binding domain, optionally the CD8 antigen-binding domain being a VHH and comprising (1) the following complementarity-determining regions (CDRs): HCDR1 with the amino acid sequence of SEQ ID NO: 109, 116 or 117; HCDR2 with the amino acid sequence of SEQ ID NO: 110; and HCDR3 with the amino acid sequence of SEQ ID NO: 111; or (2) comprises a VH region comprising an amino acid sequence with at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 112, 118, 119 or 120.
30. Antibody, according to any one of claims 8 to 27, characterized by further comprising a third antigen-binding domain, optionally the third antigen-binding domain binding to CD8 or binding to a target other than the target antigen-binding domain. Petition 870260111560, dated 10 / 29 / 2026, pp. 106 / 219 10 / 11 31. One or more nucleic acids characterized by encoding the antibody as defined in any of the preceding claims.
32. Vector characterized by comprising the nucleic acid(s) as defined in claim 31.
33. Isolated host cell characterized by comprising the nucleic acid(s) as defined in claim 31, or the vector as defined in claim 32.
34. A method for producing an antibody as defined in any one of claims 1 to 30, characterized by comprising cultivating the recombinant host cell as defined in claim 33, under conditions for the production of the antibody molecule.
35. Method according to claim 34, characterized by further comprising isolating and / or purifying the antibody molecule.
36. Pharmaceutical composition characterized by comprising the antibody as defined in any one of claims 1 to 30 and a pharmaceutically acceptable carrier.
37. A method for treating a disease in a patient who is in need of such treatment, the method being characterized by comprising administering to the patient an effective amount of the antibody as defined in any one of claims 1 to 30, or a pharmaceutical composition as defined in claim 36.
38. Method according to claim 37, characterized in that the disease is cancer.
39. Antibody, according to any one of claims 1 to 30, or pharmaceutical composition, according to claim 36, characterized in that it is intended for use as a medicament, optionally the antibody being a multispecific antibody.
40. Antibody, according to any one of claims 1 to 30, or pharmaceutical composition, according to claim 36, characterized by Petition 870260111560, dated 10 / 29 / 2026, page 107 / 219 11 / 11 being intended for use in the treatment of cancer, optionally the antibody being a multispecific antibody.
41. Use of the antibody, as defined in any one of claims 1 to 30, or of the pharmaceutical composition, as defined in claim 36, characterized in that it is intended for the manufacture of a medicament for the treatment of cancer, optionally the antibody being a multispecific antibody. Petition 870260111560, dated 10 / 29 / 2026, pp. 108 / 219
